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Abstract of Thesis 
 
Characterization of a novel, low shear lattice bioreactor 
for expansion of human mesenchymal stem cells 
 
By Andrew Barney Burns 
 
Keck Graduate Institute of Applied Life Sciences: 2019 
 
Human mesenchymal stem cells are an ideal candidate for stem cell therapies. They have 
been researched since the 1960’s and can differentiate into many desired functional cell 
types without undergoing teratogenesis. However, higher yields are needed for a 
marketable, successful stem cell therapy. To accomplish this, cells will have to be 
cultured to expand them to therapeutically relevant dosages for multiple patients. 
Bioreactor production is an ideal method to solve this problem. 
The aim of this thesis is to test and validate a novel bioreactor for the cultivation of 
human mesenchymal stem cells. In this work, we investigate a novel suspended matrix 
for the culture on human mesenchymal stem cells (hMSCs). Initially we investigated 
various fiber meshes, both random and structured, for stem cell growth and morphology. 
We also investigated hMSC proliferation on rigid polymers commonly used in 3D 
printing. We then took the conditions that worked best in 2D culture and tested them in a 
small-scale model of the Express bioreactor from Sepragen.  
We have assessed cell growth on 3D printed Polylactic Acid (PLA) matrices and 
developed a scale down model bioreactor for development and characterization. 
Computational Fluid Dynamic (CFD) modeling was used in parallel with the described 
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in-vitro experimentation to characterize shear profiles. From the CFD we were also able 
to predict a flow rate which resulted in almost zero shear. What we found was that 
hMSCs readily form confluent monolayers on the PLA lattice, and retain their surface 
marker expression and stemness. When combined with a short hypoxic treatment, the 
cells performed better than control flasks, resulting in a four-fold increase from seed with 
no impact on biomarker profile and differentiation ability. 
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1.1 STEM CELL THERAPY 
Stem cell are simultaneously novel and well researched. They were first therapeutically 
used in the 1960’s before being formally named, but have recently gained more attention 
in the field of regenerative medicine.1 This resurgence in stem cell research is based in its 
ability to both self-renew and differentiate into functional cell types. Stem cells differ by 
their time and source of harvest and are classified by their potency; Potency here refers to 
the number of different cell types the stem cell can become. The potency classifications 
for stem cells are: totipotent, pluripotent, multipotent, and unipotent. Totipotent cells are 
able to differentiate into all cell types in the body, as well as placental tissue. Pluripotent 
cells can become all cells of the body. Multipotent cells can become all cell types of a 
certain germ layer. Unipotent stem cells are restricted to one cell type and have been 
simply referred to as progenitor cells.2 A comparison of stem cell types in regards to 
therapeutic potential can be found in Table 2-1. 
Pluripotent human Embryonic Stem Cells (hESCs) are collected from the inner cell mass 
of the blastocysts. These cells can differentiate into all three germ layers and their 
resulting tissues.3 These cells have had a charged ethical history, as a fertilized oocyte 
must be sacrificed to harvest these cells. In 2001 the Bush administration placed stringent 
regulations on hESC research, resulting in defunded embryonic stem cell research using 
primary harvested lines.4 Stem cell research was still conducted, but was limited to 
established lines, such as H7 and H9 hESCs. This complicated hESC research, as 
laboratories had to split funding and lab space by private investors vs government 




funding. It also was detrimental to hESC research, as the available lines were not 
genetically diverse.5 Later, the Yamanaka and the Thompson labs both discovered ways 
to genetically alter cells and induce a pluripotent state in the cells.6,7 Among the 
transcription factors the two labs discovered, the two main genes needed are Oct4 and 
Sox2.  Additional alternatives include Nanog, FL4, and C-Myc.6,7 Cells treated with these 
factors have been deemed induced pluripotent stem cells (iPSCs). This cell type usually 
uses a feeder cell culture such as mouse embryonic fibroblast to provide a supportive 
culture environment for the cells. Additionally, trypsin cannot be used when passaging 
these cells, as hESCs tend to apoptose when placed into single cell suspension. Because 
of this, enzymes like accutase are used for cell-substrate detachment to lift cell clusters. 
Multipotent stem cells are found in all tissues of the body.8 They are hypothesized to be 
surrounded by support cells, forming a favorable niche for the cells to stay quiescent until 
called to action via cytokines or stress. These stem cells can give rise to cells only of their 
respective germ layer. Though multipotent stem cells have less potency compared to 
iPSCs, they are the most studied type of stem cell. This long history stems from their first 
use as a treatment for Leukemia. 
The first stem cell therapy was performed via bone marrow transplant over 50 years ago 
by Dr. E. Donnall Thomas. This treatment replaced the immune system of a leukemia 
patient by harvesting bone marrow from a healthy donor and placing it into the ablated 
bone of the patient.1 The transplanted bone marrow brought with it both hematopoietic 
stem cells and bone marrow derived mesenchymal stem cells. Since the donor and 
recipient were twins, there was no issue of host vs graft disease. As research in tissue 
transplantation continued, it was discovered that Human Leukocyte Antigen (HLA) was 




key in graft vs host disease. Allogenic grafts are now possible by matching donor and 
recipient based on HLA. This breakthrough opened the door for stem cell treatments. 
Companies like AlloSource, NuVasive, Osiris, OrthoFix, and others have been approved 
as combination medical devices and Human Cells and Tissues/Products (HCT/P), and are 
currently sold in the United States under the guidance of 21 CFR 361.9 They have been 
used for bone regeneration, soft tissue repair, and spinal bone regeneration. They have 
been approved through the 501k pathway, meaning the device must show equivalence to 
an already approved medical device. For the transplanted cells to remain compliant under 
21 CFR 361, the cell product used with these devices must remain minimally 
manipulated, otherwise it would have to be approved as a BLA or another more 
complicated avenue. One issue specifically with HCT/P is that they do not have to show 
equivalence or go through normal clinical trials for approval. This can result in 
ineffective therapies and can potentially harm patients. 
The current demand for stem cells far exceeds their supply. Recent projections estimate a 
31.1% compound annual growth rate of the stem cell market from 2016 to 2022.10 As 
demand grows, there have been various attempts to culture these cells in the hope of 
increasing the supply for allogenic stem cell therapies and their testing. Cell culture and 
cryopreservation are expected to cost over $10 billion by 2020.11 Conventional culture 
systems cannot produce these numbers, as culturing stem cells is comparatively harder 
than other cells.  
Stem cells are very sensitive to chemical and mechanical cues. Such forces can cause the 
cells to differentiate, become quiescent, or apoptose.12,13 They are also slow growing, 
which pushes out harvest time and increases the risk of contamination. The media also 




must contain recombinant factors, which makes it expensive and usually undefined.9 
Furthermore, they are adherent dependent, and as such will not readily grow in 
conventional bioreactors for culture of CHO or other suspension-adapted cell lines. 
Because of this restriction, scale out, rather than scale up, methods of culture are 
generally adopted. 
1.2 AIM AND SCOPE 
High purity, high density culture methods for mesenchymal stem cells are necessary for 
stem cell based therapies to be fully realized. Conventional bioproduction techniques 
have been used to culture stem cells with cell based therapies in mind, however these 
techniques are generally cumbersome and prone to contamination which can result in 
impure cell populations. Here we investigate a custom system for high purity, scalable 
culture of human mesenchymal stem cells. The main drawbacks of other systems include 
lack of cell monitoring, shear stress from mixing techniques, and heterogeneity in the 
system due to a combination of these factors. These prompted the design of the core of 
the system to facilitate mesenchymal stem cell growth in a homogenous lattice matrix 
comprised of biocompatible polymers and materials which would not lead to impurities 
in the cell harvest. 
1.3 SIGNIFICANCE OF THE RESEARCH 
Stem cell culture is inherently more difficult to scale than conventional cell cultures. 
hMSCs are very shear sensitive, which leads to low and impure cell harvests. Here we 
show a system that performs better than conventional spinner flasks and tissue culture 
flasks. The research was performed as a means of high density, pure stem cell culture. 




The footprint is less than that of a standard T75 tissue culture flask, but produces double 
the yield with better purity.  
1.4 OVERVIEW OF THE STUDY 
The background focuses on hMSC bioproduction to provide understanding of existing 
systems, both in their advances and their shortcomings. The following chapters outline 
the testing of various polymer types for cell culture and their basic surface chemistries, 
oxygen tension and its effect on stem cell proliferation and stemness, culture in a 
dynamic 3D culture system, and computational characterization of the system. The 
chapters are written in the form of individual manuscripts that together provide a 
complete overview of the tested system in regards to hMSC bioproduction. 
2 LITERATURE REVIEW 
2.1 MESENCHYMAL STEM CELLS 
Adult Mesenchymal Stem Cells (MSCs) are an anchorage dependent stem cell harvested 
from adult tissues. Typical sources include the marrow of the iliac crest, the head of the 
femur, adipose tissue, peripheral blood, Warton jelly, and umbilical cord blood.14  MSCs 
were first described by Dr. Friedenstien, who was able to show the existence of a clonal 
subpopulation of cells in the spleen and blood producing organs of mice.15 Their harvest 
amounts vary drastically by their source, with up to 500 times higher yields from fat than 
from bone.14,16,17 They are described as fusiform, fibroblast-like cells, and often appear 
spindle-like under phase contrast.18 They are characterized via surface marker expression, 




gene expression of stemness genes, and the cells that they can differentiate into. Research 
has shown that hMSCs are positive for the cell surface markers CD166, CD105, CD90 
CD73, CD44, CD29, and STRO1 and negative for CD45 CD34, CD19, and CD14.18–21 
Some variation in expression of these markers exist, but this may be explained by 
variations in the culture methods as well as the age of the cell.18 Due to variation, the 
International Society for Cell Therapies (ISCT) has released documentation stating that 
the minimal criteria to characterize hMSCs for therapies is: greater than 95% expression 
of CD105, CD73, and CD90, and lack CD45, CD34, CD14 or CD11b, CD79α or CD19, 
and HLA class II.22 They must also adhere to plastic, and maintain their osteocyte, 
adipocyte, and chondrocyte differentiation ability. Though not an ISCT criteria, it has 
been shown that they express the stemness genes SOX2 and NANOG.23 They can 
differentiate into cells of the mesoderm, including adipocytes, osteocytes, chondrocytes, 
myocytes, cardiomyocytes, and tenocytes (Figure 2-1).24 There has also been some 
investigation into the still controversial transdifferentiation of hMSCs, resulting in 
pancreatic islet cells, corneal epithelium, and nervous tissue.25–27 This type of change 
results in the cells entering a dedifferentiated state similar to IPSCs, then differentiating 
down another germ lineage.  
Differentiation is normally controlled through a mix of cytokines, cell mediated cues, and 
external forces. Cytokines and soluble factors can be added to basal media and change 
gene expression through cellular pathways.28–30 External forces such as shear and 
topologies can also lead to differentiation. Osteocyte differentiation can occur with 
exposure to as little as 10 dynes/cm2, and higher rates can lead to apoptosis.31 Culture 
methods emphasizing strong binding to ECM or substrates show less stemness, while cell 




culture comprised of mainly cell-cell junctions promoted stemness.23 Nanotopographies 
have also been implicated in stem cell differentiation, leading to osteocyte 
production.32,33 Substrate stiffness also plays a large role in hMSC fate; softer substrates 
tend to produce chondrocytes and adipocytes, while stiffer materials favor osteocyte 
differentiation.34–36 The explanation for this is that the culturing substrate matches the 
final environment of the cell, which leads it to differentiate into the cell best suited for 
that environment. 
hMSCs tend to reach senescence after 24 to 40 population doublings, depending on the 
age of the donor. The younger the donor, the more doublings were possible before the 
hMSCs showed signs of senecensce.18 This is caused by several factors including 
damages to DNA, changes in mitochondria, abnormal protein accumulation, and the lack 
of telomerase to maintain proper telomere length.37–39 
Their ability to differentiate into such a variety of functional cell types, combined with 
proven benefit in the treatment of inflammatory diseases, along with their ease of 
culturing compared to other types of stem cells has made them crucial candidates in 
regenerative medicine.40,41 This is because hMSCs are immunotolerant and 
immunomodulatory cells.42,43 It has been shown that this is partially due to a paracrine 
signal molecule secreted by hMSCs.44,45 One example of hMSCs’ role in the immune 
response was shown when hMSC conditioned media inhibited t-cell activation. This 
immunomodulation has become a unique characteristic used in identifying these cells.46,47 
Part of this ability may come from secretory vesicles known as exosomes, which are 
discussed later in the text. A brief list of diseases where hMSCs are currently being 




investigated includes cardiovascular diseases, diabetes, various immunomodulatory 
diseases, and bone disorders. 
 Myocardial Infarction 
More commonly known as heart attack, Myocardial Infraction (MI) is caused by 
ischemia to the heart. This results in damage to cardiomyocytes, decreased heart function, 
and possibly death. There are approximately 790,000 new MI cases every year in the 
United States,48 and costs approximately $108 billion each year.49 Though hMSCs have 
the ability to differentiate directly into cardiomyocytes and replace lost function, the 
exact mechanism of heart repair is still unclear. Resurgence in cardiac function may also 
come from angiogenesis, which results in the growth of new vessels which reestablish 
blood flow to infarcted areas of the heart. 50–52 It has also been found that hMSCs have a 
cytoprotectant effect on cardiomyocytes.53 In mice, autologous mesenchymal stem cell 
transplantation into the heart results in a 40% increase in capillary density, as well as 
increased ventricular contractility.51 A human clinical study investigating the heart 
function restoration through hMSC implantation found that left ventricular ejection 
fraction of the heart increased by 3.84%.54 Incidence of re-hospitalization for heart failure 
also dropped in hMSC treated patients.54  
Research has also shown that the factors released from hMSCs were able protect 
infarcted regions from cell necrosis and prevent scar tissue formation in rats.55 This was 
achieved by transplantation of a cell-laden hydrogel onto the infarcted region. Pore sizes 
in the gel construct used to anchor cells to the heart were 11nm, small enough to allow 
signaling molecules, but would stop larger extracellular vesicles or cells themselves from 




escaping the hydrogel. 2x106 cells per mL were needed to achieve similar levels of 
ejection fraction and stroke volume as control groups.  
 Diabetes  
Diabetes is a disease in which the body cannot regulate glucose levels in the blood. This 
can cause complications such as neuropathy and damage to microvasculature.56,57 
Researchers have shown that hMSCs can be used to treat neuropathy and vascular 
damages resulting from diabetes mellitus.57 hMSCs have been found to play an important 
role in in tissue repair to lower blood glucose levels.58,59 They are also able to treat 
diabetic neuropathy through a paracrine effect.56,57,60 Vascular Endothelial Growth Factor 
is one the many cytokines secreted by hMSCs and is the main chemokine of 
angiogenesis. When combined with the immunosuppressive properties of hMSCs, this 
can restore lost microvasculature.56,57,61 Adult hMSCs also have been implicated in 
neuroprotection. Implantation of hMSCs into animal models of Parkinson’s disease 
showed a decrease in dopaminergic cell and Perkinje cell loss, showing their 
neuroprotective nature.62 
Research has also shown how hMSCs repair both beta islet cells and renal glomeruli in 
mice models of diabetes. hMSCs lowered blood glucose and increased circulating levels 
of insulin.59 The stem cells were introduced through intracardial infusion, but human 
pancreatic islets and beta cells were found in the pancreas. Human cells were also found 
in the kidneys, making up parts of the glomerulus.  




 Skeletal Diseases 
Osteoarthritis affects 27 million people in the United States and is the most common joint 
disorder in the country.63 This disorder causes articular cartilage damage, resulting in 
bone on bone movement, inflammation of joints, and pain. It is the leading cause of 
disability in the elderly, and it is estimated that 10-15% of adults over 60 years of age 
will develop osteoarthritis.64 Current therapies do not repair the damage causing the pain, 
and merely treat the symptoms rather than the cause. In a human trial, 108 hMSCs were 
injected into the articular cartilage of patients. The patients showed significant 
improvement in pain and function with no adverse events.65 Cartilage defects were also 
reduced through regeneration of hyaline-like articular cartilage. The hMSC paracrine 
effect has also shown importance in treatment of osteoarthritis, decreasing inflammatory 
injury and decreasing chondrocyte migration.66,67 Because of this, many researchers are 
currently investigating the secretome of hMSCs for treatment of osteoarthritis.66,68,69 
Osteoporosis is the progressive loss of bone mass over time. It is generally age related 
and affects millions of individuals worldwide.70 Bone loss can be so significant that 
patients can become bed ridden from sever fractures. Normally osteoblast cells rebuild 
the bone in balance with osteoclasts resorbing old bone. In osteoporosis, the balance is 
skewed where breakdown outweighs deposition of new bone. Current therapies mainly 
prevent further bone loss. Research has shown that hMSCs are a possible means of 
treating this disease and rebuilding lost bone.70 This is because of their ability to 
differentiate into osteoblasts and directly increase bone mass.  
One shared problem across these various diseases is that they all theoretically require 
massive amounts of cells. For MI, it is estimated that up to one billion cells are needed to 




substantially reverse damage to the heart.54,71,72 For diabetes and osteoporosis, it is 
estimated that hundreds of millions of cells are needed for successful therapies.65 Harvest 
alone cannot yield the necessary numbers to treat millions of patients, thus culture is 
necessary for commercialized allogenic hMSC therapies to become reality. 
2.2 HMSC CULTURE 
MSCs are generally regarded as easier to culture than embryonic stem cells and are also 
of less ethical concern. Unlike ESCs and IPSCs, they do not undergo teratogenesis, which 
eases regulatory concerns. These cells are described to have a fibrotic morphology, and 
do not require co-culture with support cells like hESCs have historically needed.73 Unlike 
their pluripotent counterparts, they can also be passaged as single cells in which 
passaging must be done with accutase or collagenase to leave cell clusters.73,74 This 
makes subculturing much easier because it is possible to attain distribution of single cells. 
This also has the added effect of increasing homogeneity in cell culture. 
Media used for stem cells is generally costly, and hMSCs are no exception. One reason is 
because serum and cytokines are needed in the media to maintain stemness. Typically, 
the two main cytokines for hMSC culture are recombinant human insulin like growth 
factor one (IGF-1) and recombinant human beta fibroblast growth factor (b-FGF). Fetal 
Bovine Serum (FBS) is also added to the media. FBS generally ranges from 5% to 10% 
v/v of media composition, usually in Dulbecco’s Minimum Essential Media (DMEM) or 
alpha MEM.75 It is supplemented with amino acids and can have antibiotics added to 
combat microbial contamination. Due to the high cost of media, it is difficult to run such 
systems in perfusion, especially in academia. Because serum is used, the media is 




chemically undefined. For regulatory purposes, there is active research into alternatives 
for serum. Xeno-free alternatives like human platelet lysate have been used, and though 
they are generally recognized as safer than serum, there is still a possibility of 
transmitting human diseases and infectious agents. Human platelet lysate is also 
expensive, as it must be harvested, stringently tested, and processed before use. 
Chemically defined media is commercially available as well, which forgoes all serum and 
its harvested likeness. There is much variation of biomarker characterization, cell 
proliferation, and subsequent stemness of the cells harvested between all these various 
types of media,75,76 all of which are qualities used by the ISCT as means of quality 
control. 
Traditionally hMSCs are cultured on t-flasks. This static 2D culture can produce 
relatively pure stem cells in a reasonable time. In the lab we found a consistent cell yield 
of 1.2x106 to 1.4x106 BM-hMSCs from one T75 flask, equating to around 60,000 to 
70,000 cells/mL. To scale this method and increase cell yields to meet the quantities 
needed for successful therapies, researchers have used roller bottles and Multiplate 
stacks. Roller bottles increase surface area by allowing cells to grow on the walls of the 
cylinder. The bottles are placed on their sides, filled with just enough media to cover the 
bottom side, and gently rolled via a rack system. As the bottle turns the cells are 
systematically washed with media. This style of culture has fallen out of favor for the 
simpler and larger SA:V ratio of Multiplate flasks. Multiplate stacks like Nunc Cell 
Factory (Thermo Fisher) and the Corning Cell Stack (Corning) combine many flat culture 
areas into one flask. They contain between 1 to 40 stacks, with newer system containing 
up to 120 layers.77 Both roller bottles and Multiplate systems ease operator burden, but 




still have their limitations; it is difficult to monitor and control the cells, and hard to 
ensure even distribution of the cells across the culture surface. Improper seeding and lack 
of monitoring can lead to poor yields and heterogeneity in harvest. As such, more 
controllable bioreactors have been a hot topic of research regarding stem cell culture. 
The goal of scale out systems using such bioreactors is to produce high quality stem cells 
in large enough quantities for therapeutic needs. It is estimated that between 106 and 109 
stem cells per kilogram weight per patient are needed to treat diseases such as diabetes 
and myocardial infarction.72,78–81 This large number is due the combination of attrition of 
stem cells through migration, unwanted differentiation, and apoptosis. The only way to 
reach the large numbers needed for therapeutic dosages is through cell culture. 
Furthermore, more than one dose may be necessary to combat this attrition and fully treat 
the disease. When required the dosage is multiplied across the thousands of patients 
included in a phase III clinical trial, it becomes clear why the vast majority of allogenic 
trials currently listed are in Phase I and II. Bioreactors have been investigated for higher 
density stem cell culture to address this. 
2.3 BIOREACTOR CULTURING METHODS 
Conventional bioreactors for suspension-adapted cell culture are inherently unfavorable 
for stem cell culture. They are traditionally impeller driven, resulting in higher than 
desired shear for the delicate stem cells. They also provide no surface for the cells to 
adhere and grow. This means that more customized solutions for old reactor styles, or 
completely new reactors must be made to match the requirements of stem cells. When 
designing such systems for cell growth, the main points of consideration are: the surface 




area available to the cells, the hydrodynamic forces the cells experience in such a system, 
nutrient gradients in the system that may result from non-impeller driven mixing, and 
ways of detecting and sampling the cells. With these factors in mind, two main methods 
have evolved for stem cell culture; suspension cultures using microcarriers, or 
immobilized/fixed bed reactors. From a research landscape study, it was found that the 
majority of studies (57%) used bone marrow derived hMSCs (BM-hMSCs).75 It also 
found that microcarriers were the favored method of expansion (52.2%). A comparison of 
fold increase vs hMSC source also showed that adipose derived hMSCs (AD-hMSCs) 
generally achieved higher average expansion factors compared to other sources. One 
point worth mentioning is that a group of high performing multiplate static cultures 
reported in this paper came from the same lab which was seeding at 30-40cells/cm2 
(compared to the recommended 5000cells/cm2).75 Evidence has shown that lower seed 
densities increase the rate of population doubling, which increases the expansion factor.82 
Low density seeding also has the benefit of maintaining stemness, as researchers found 
that cell-cell contact at high confluency decreased CD105 and had a lower percentage of 
senescent cells.82  Some other attributes that a reactor should have are: scalability, ease of 
use, ease of harvest, automation, and cost effectiveness. A comparison table of culture 
methods can be seen in Table 2-2. 
 Microcarrier Based 
The most common route has been to use microcarriers in traditional bioreactors for 
suspension cell types. These are polymer spheres ranging from 100 to 300 microns in 
diameter, and provide the stem cells a surface on which to grow while in a suspension 
system. Using these carriers allow high density cultures because of the large surface area 




to volume ratio, with minimal design changes needed on traditional stirred tank 
bioreactors. Cells are adherent on free-floating structures, so direct sampling of cells is 
easily performed by a media draw. Microcarriers can vary in composition from non-
degradable plastics, to dextran, to enzymatically digestible polymers.9 Some macroporous 
carriers allow the stem cells to grow inside of the microcarrier itself, protecting it from 
strong hydrodynamic forces.83  These carriers can be used in conjunction with various 
bioreactor culture systems, the most common being stirred tank reactors and wave bags. 
2.3.1.1 Stirred Tank reactors and Spinner Flasks 
Traditionally used with CHO and considered the workhorse of bioprocessing, spinner 
flasks and stirred tank reactors are commonly used for seed train and cell expansion. 
They consist of a centrally located, magnetically or mechanically driven impeller. The 
impeller provides even distribution of gas and nutrients to cells. Oxygen transfer can be 
performed using a submerged sparger below the impeller, or simply though the gas-liquid 
interface at less than 1 liter.77 Using such a system provides more control over cell culture 
conditions than static flasks, as agitation provides a more homogenous environment and 
inline process parameters can be used to monitor metabolites, pH, temperature, and 
Dissolved Oxygen (DO).9,77,84,85 These systems can then be run in fed batch or perfusion 
to adjust parameters accordingly and maintain an optimal environment for cell growth. 
Cell expansion varies by harvest source of the mesenchymal stem cells, but falls roughly 
between 0.2x106 and 2x106 cells/mL.46,84,86 By using large scale single use STBR 
researchers were able to achieve 43 and 58 fold increase in adipose derived hMSCs.24,46 
However, the impeller used in this system imparts high shear. hMSCs are very shear 




sensitive, and higher than normal values of shear can lead to cell death and 
differentiation.  
2.3.1.2 Wave bags 
This system utilizes a flexible bag placed on a rocking table. Bags are loaded with media 
to the desired volume, and gas is overlaid into the head space to inflate the bag the rest of 
the way. Gas exchange and media mixing is controlled by rocking the table. Speed and 
angle are what control the rates of mixing. The resulting back and forth movement results 
in a wave that moves through the media, mixing the media and suspending MSC laden 
microcarriers. This system can also have the same inline process monitoring capacity as 
stirred tank systems. Researchers using this system have reported between 0.9x106 and 
1.9x106 cells/mL and an overall 5 to 15 fold increase in adipose and placental derived 
hMSCs after culture.87,88 There is some concern that the energy required to keep 
microcarriers in suspension may be high enough to induce a breaking wave, thus 
resulting in very high shear. 
2.3.1.3 Paddle Driven/Vertical-Wheel bioreactors 
These singe use systems are driven by a centrally located paddle wheel. The bottom of 
the reactor is U-shaped with tight clearance (the wheel is approximately 85% the 
diameter of the singe use bag insert) between the vertical wheel and the bottom. This 
provides a strong sweeping force to suspend the cells with low power input.89 The wheel 
is mounted horizontally to the systems, such that the direction of motion drives fluid up, 
while two axial paddles provide sideways liquid handling, generating a folding action.90 
The paddles of the wheel are large enough that very slow rotation provides sufficient 




lifting force to mix the microcarriers while inferring relatively low shear, creating a 
favorable culture environment for microcarrier bound BM-hMSCs.91  
 Non-Microcarrier based systems 
Unlike suspended microcarriers, there are other commercially available systems where 
the culture substrate is stationary. Media is flowed around the substrate or over the cell 
culture surface. As a whole, these systems offer the same advantages as the microcarrier 
based systems mentioned previously (real-time measuring of process parameters), but 
since the culture area is not in free suspension, direct cell sampling and visualization is 
much harder. However, these systems have the benefit of incredibly high SA:V ratios and 
decreased purification at cell harvest because of the geometry and immobility of the 
culture substrate. As with microcarriers, enzymes are typically used to detach the cells 
from their substrate and from other cells. 
2.3.2.1 Packed bed 
Another avenue of stem cell bioproduction includes immobilized/fixed bed reactor-based 
systems. The culture material can either be packed or held in place (fixed bed) while 
media is perfused through the system, or the material can be floating (fluidized bed) in a 
chamber while the media is perfused through it. These systems generally use randomized 
fibers to provide a large surface area to volume ratio for stem cell culture. Cells grow 
adherently on the surface of fibers while media is perfused through the porous fiber 
matrix. Researchers have reported fold expansions of 9.2 to 38.7 in such systems using 
bone marrow and umbilical cord hMSCs.24,92 The iCELLis by Pall is a commercially sold 
fixed bed system which uses PET as its culture substrate.  




2.3.2.2 Hollow fiber 
Normally used in downstream filtration, cells can grow in either the lumen or around the 
outside of such fibers, and media can be passed through the fibers. An advantage of this 
system is can mimic laminar flow through vessel very well. However, as mixing is not 
handled in a turbulent manner, media gradients can form in such fiber-based systems. 
And since the fibers are locked in place, direct sampling of cells is much more difficult 
than with microcarrier based systems. Papers report successful hMSC expansion in GMP 
compliant quantum cell hollow fiber system.93–95 and expansion factors of 6.7 to 31.4 
were reached using BM-hMSCs.93,94,96,97 
2.3.2.3 Parallel plate 
Lastly, a derivative of Multiplate systems is the parallel plate bioreactor. This system is a 
stack of plastic plates much like static multistack/multiplate flasks already mentioned. 
The difference here is that media is flowed from the center radially outward on multiple 
plates stacked in one system. Much like hollow fiber-based reactors, nutrient gradients 
can form, and direct sampling of the cells is near impossible in such a system. However, 
both fiber based and microcarrier based systems boast more surface area to volume than 
these systems. One study reported an expansion factor of 3.9 using periosteum derived 
hMSCs.98 
2.4 POLYMERS USED IN CULTURE 
Polymer composition and stiffness are integral in stem cell culture. Stiffer materials have 
been shown to increase osteogenesis in hMSCs.36 Cells cultured on polymers with similar 
elastic modulus to cancellous bone have been shown to readily differentiate into 




osteocytes and start calcium deposition. Conversely, hMSCs cultured on more elastic 
substrates will differentiate into chondrocytes.34 The hydrophilicity also has a direct 
impact on cell stemness and proliferation. Hydrophilic surfaces decrease cell binding, 
which in turn increases cell stemness.23 The reverse is also true, where the greater the cell 
adhesion to the substrate due to hydrophilic surfaces decreases differentiation potential. 
Polyethylene Terephthalate (PET) and Polyethylene Terephthalate Glycol (PETG) are 
both thermoplastic polymer resins from the polyester family. PET and its blends have 
been used as a cell culture substrate. It can be electrospun in nanofibers or 3D printed 
into shapes.99 PET fibers are currently used as the cell scaffold in the iCELLis reactor. 
Researchers discovered that a PET 3D fiber matrix used in the iCELLis reactor both 
sustained hMSC culture for 21 days, and increased both CD105 and CD29 markers.100  
Polystyrene (PS) is the plastic of choice for cell culture. Tissue culture flasks are made of 
PS and treated with plasma or exposed to radiation to expose hydroxyl groups on the 
surface.101 These functional groups promote cell attachment and proliferation. This 
process exposes hydroxyl groups, which can be used to both coat the dishes with 
proteins, and directly promote cell adhesion. 
Polycaprolactone (PCL) is a synthetic polymer that has gained interested in cell culture 
due to its biocompatibility and biochemical properties.102 It has been electrospun into 
nanofibers for the culture of hMSCs and their differentiation into osteocytes.103 
Poly Lactic Acid (PLA) is easily 3D printed and generally recognized as safe by the 
FDA. It has a Young’s modulus similar to bone, matching the niche of bone derived 
hMSCs. Its hydrolysis product is lactic acid, a compound normally found produced by 




metabolism. Previous research has shown that plasma treatment of nonwoven PLA 
scaffolds promotes stem cell adhesion and growth.104,105 
Hydrogels are an alternative to rigid polymers and plastics. They have been successfully 
used for both stem cell culture as well as a means of directing stem cell fate.106 Some 
natural polymers used include alginate, Hyaluronic acid, Chitosan, Collagen, and gelatin. 
Artificial hydrogels have also been used for this purpose and result in a Xeno-free culture 
surface. These include polyvinyl alcohol, polyethylene glycol, and polyacrylamide. 
Special polyacrylamide gels are thermoresponsive, allowing different characteristics by 
varying temperature. Poly(N-isopropyl acrylamide) (pNIPAAM) has been used to culture 
stem cells and allows for non-enzymatic cell lifting.107–109 
These polymers have been blended, electrospun, and coated to modulate 
biocompatibility, increase binding and proliferation, and allow for resorption into the 
body. The latter is done with the intent of stopping stem cells from migrating away from 
the surgical site, thus increasing the effectiveness of the stem cell therapy.  
 Coatings 
Most polymers used for cell culture are blended with proteins or coated with proteins 
after manufacturing to promote cell adhesion and growth. The most common coatings are 
animal derived, and the choice is largely dictated by the cell that is being cultured. 
However, the most ubiquitous is gelatin, a denatured form of collagen. 
Usually provided as a powder, porcine gelatin is dissolved into deionized water to make a 
0.1% solution. This can then be plated onto cell culture surfaces to deposit denatured 




collagen onto the surface.110 This provides a more favorable surface for cells to adhere to 
by providing RGD residues for integrin mediated binding.111 
Collagen anchorage is dependent on cell recognition of GxOGER residues.110 Collagen I, 
II, and II are rich in this peptide sequence.112 Researchers have found that there is more 
cross-linking between collagen fibers in 3D culture, decreasing integrin mediated binding 
of cells.110 They deduced that cell adhesion was mainly due to entrapment of cells within 
the cross-linked ECM. 
Laminin is normally found in the basement membrane separating epithelium from the 
underlying tissue.113 In studies conducted with cancer cell lines it was found that laminin 
promoted cell motility.114 This may be useful as a cell coating where passaging is 
performed by addition of new surface area for the cells to migrate to and culture out, 
eliminating the need for enzymatic digestion based passaging. 
Cell adhesion to fibronectin is integrin mediated via RGDS recognition sites.115 
Fibronectin has been shown to promote osteocyte differentiation in hMSCs.116 It is 
normally found circulating in blood plasma and plays a large role in wound healing.117  
Vitronectin is a glycoprotein found predominately in the serum and in bone.118 It binds 
integrin to promote cell adhesion and migration.119 A recombinant form of fibronectin is 
commercially available, easing regulatory concerns.  




2.5 ADDITIONAL PARAMETERS IN STEM CELL PROLIFERATION 
AND PURITY 
 Gas control 
Research has shown that another method of controlling hMSC proliferation and stemness 
is through control of gasses. Physiological oxygen percent in the bone marrow is between 
1% and 5%.120,121  By matching oxygen tension normally found in their niche, researchers 
have seen significant increases over conventional culture techniques.122,123 Biomarker 
profile does not suffer, and cells can still readily differentiate into normal cell types.124,125 
Companies like Xcell Biosciences have integrated hypoxic culturing options into their 
Avatar incubators, as well as hyperbaric conditions, and have shown that this 
combination increases marker expression and proliferation with stem cells.126 This effect 
is through hypoxia inducible factors (HIFs) and their downstream effects.123,127 HIF has 
also been shown to increase stem cell survival and proliferation.128 Genetically modified 
stromal cells showed increased engraftment in ischemic heart tissue.129 
2.6 OTHER CONSIDERATIONS 
 Downstream processes 
One commonly overlooked hurdle in stem cell therapy is the downstream purification of 
these cells.75 The level of purification needed is heavily reliant on the quality of cells 
produced, as well as the materials used in the culture of these cells. As such, some focus 
has been placed on microcarrier composition, resulting in digestible polymers and simple 
filtration devices to remove microcarriers.9,130–132 This removes the otherwise required 




filtration step to ensure complete removal of microcarriers from cell harvest. The same 
applies to porous medium, where thermoresponsive coatings aim to eliminate enzymatic 
cell lifting steps altogether.109,133–135 Biocompatible polymers have also shown some 
promise in reactor culture, cutting the concern of leachables considerably, while also 
possibly eliminating cell removal altogether.108 Implantation of a cell laden scaffold make 
of a biocompatible or biodegradable polymer would also help stop stem cell migration to 
other parts of the body, theoretically increasing efficacy of the therapy and would also 
eliminate the need for cell removal from the culture substrate.103,104,131,136 Such processes 
would drastically decrease downstream requirements, though buffer exchange may still 
be necessary. 
 Cryopreservation 
An allogenic process for hMSC production would need to be cryopreserved for large 
scale distribution. The cells would be shipped to centers where administration would 
occur, as it is not feasible to ship and store non-cryopreserved cells. Researchers have 
shown that high viability cell recovery under serum free culture and freezing conditions 
is possible.137 It is worth noting that this process still uses conventional centrifugation 
steps to both suspend cells in cryopreservation media before freezing, and to remove 
cryopreservatives. These techniques do not scale well, and concentration and buffer 
exchange steps may be better scaled using Tangential Flow filtration. 
This downstream step has been tested for hMSC concentration and media exchange with 
good results. Researchers found that though the stem cells are easily damaged by shear in 
such a system, it can still be used to clarify BM-hMSCs from microcarriers and 
concentrate them for further processing.138,139 





Exosomes are extracellular vesicles secreted by hMSCs. They are between 30nm and 
150nm in diameter and contain cytokines, various types of RNA, and DNA.140–142 
Exosomes originate from early endosomes that are modified by the fusion of other 
intraluminal vesicles.143 They are released after fusion with the plasma membrane. 
Exosomes have been shown to help heal wounds and decrease inflammation.144 
MicroRNAs (miRNAs) are one part of these vesicles, and it is thought that they are a 
main contributor of free miRNA in circulation.145,146 miRNAs have been shown to play a 
role in disease and have been investigated as therapies for inflammatory diseases, ocular 
diseases, bone and cartilage disorders, and even some forms of cancer. 66,69,142,144,145 
Because exosome-based therapies do not use the whole cell itself, the road to market 
approval may be easier and faster. The exosomes can be characterized and do not pose 
the same risks as stem cells such as off target differentiation, rare occurrence of 
malignancies, and infection.147,148 A perfusion reactor would be a viable option to 
produce exosomes, as TFF would stop any cell contamination into the product while 
constant media exchange would help guard against product degradation. 
 Lab on a chip 
Drug discovery and testing are currently the costliest steps in producing drugs. 
Therapeutic candidates are screened for reactivity in vitro, and when positive targets are 
found they are progressed to animal studies to test safety and efficacy. However, animal 
testing and its overhead is very costly, and not always predictive of safety in humans.149 
One theoretical method to test drug safety on human tissue in a repeatable manner is to 
create a tissue or organ sample on a chip.150,151 The goal is not to create the entire organ 




or structure, but merely a functional subunit of the tissue.150 This technology stems from 
the ability of a stem cell to give rise to functional cell types which make up specific 
tissues. A stem cell can be cultured out and differentiated, resulting in a functional tissue. 
The resulting tissue can be tested for drug interaction more holistically than could 
otherwise be done with a specific cell type. A therapeutic agent can be tested for toxicity 
and effectiveness in closer relation to what would happen in the body. Moreover, stem 
cells from diseased patients can be used for disease modeling.152 This has mainly been 
advocated with the use of IPSCs, but may also prove useful in MSCs for testing drug 
targets for diseases of tissues derived from the mesoderm. 
2.7 CONCLUSION 
hMSCs have much potential as a marketable autologous and allogenic stem cell therapy. 
Over the past few decades scientists have made large leaps in understanding these 
extraordinary cells. One general agreement is that large scale culture is needed for a 
successful allogenic therapy to be realized. This is because of the theoretically large cell 
numbers needed for a therapeutic dose, due to in part to the sensitive nature of stem cells. 
There is no consensus on approach, as each system has its own advantages and 
disadvantages. Microcarrier based culture utilizes more characterized systems, making 
translation into bioreactors simpler. However, the impeller used in stirred tank systems 
can result in high shear. Fixed bed reactors and parallel plate reactors remove the need for 
an impeller but make it difficult to sample the system and characterize cell morphology. 
One commonality in these systems is the need for polymer selection. 
To increase binding and stemness of the cells cultured in such systems material scientists 
have investigated polymers and polymer blends. hMSCs respond to mechanical cues, 




allowing scientist to drive purity and differentiation without the need of cytokines. 
Polymer science has also been used to create a more physiologically similar environment 
to the normal cell niche. Microcarriers and fiber based systems have both benefitted from 
this, as seen by the use of biocompatible materials, special topologies, and coatings of the 
materials.  
Hypoxia has been shown in increase both stemness and cell proliferation in hMSC 
cultures. Decreasing oxygen percentage mimics the natural niche in bone, much like the 
mentality of altering polymer stiffness. This has worked as an effective and simple means 
of increase stem cell yields while maintaining cell purity.  
Cells grown in these methods have other uses than being implanted as a therapy. Secreted 
proteins and vesicles can be harvested from such systems and used themselves as a 
possible therapies. Healthy and diseased cells can be cultured out in a bioprocess and 
differentiated into tissues. The resulting lab grown tissue can be used as a test for drug 
interaction and efficacy. Both of these processes may have a more defined route to 
approval and usage then whole cell therapies. 
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Table 2-1: Pros and Cons of stem cell types in regard to bioproduction and therapeutic potential. 
Stem Cell Type Advantages Disadvantages 
Embryonic - High Differentiation Potential 
- High Passage Potential 
- Hard to Source (ethical issues) 
- Immune Response 
- Teratogenic Phase 
Induced 
Pluripotent 
- High Differentiation Potential 
- High Passage Potential 
- Easily Sourced 
- Patient Specific 
- Teratogenic Phase 




- HLA Typed and Banked 
- Immunoprivilaged 
- Easy Culture 
- Historical Use and Widely 
Researched 










Figure 2-1: Brief diagram of differentiation potential of hMSCs. Using factors and seeding techniques 
hMSCs can become many desired functional cell types. 
  






Figure 2-2: Various bioreactor systems for the culture of hMSCs. On the left are common microcarrier 
based systems, and on the left are commonly used scaffold based bioreactors. Adapted from Jossen et al.9 




Table 2-2: Bioreactor systems advantages and disadvantages for the bioproduction of hMSCs. 







environment; easy to scale up. 
High shear stress. Little nutrient 
diffusion into center of 








Support high density cell 
culture; regulate cell growth 
and differentiation; serve as 
cell delivery systems; easy to 
scale up. 
Difficult to harvest cells. Still 
some possible shear issues. 








stirred tank, RCCS 
Protection from shear stress; 
provide 3D 
microenvironment. 
Need to release the cells from 
the hydrogels. Can affect 







Suitable for hematopoietic 
stem cell culture; gentle 
mixing, low shear stress, easy 
to scale up. 
Costly. Possible sampling 
issues. Required energy for 
suspension causing high shear. 
78,158
 
Adherent Hollow fiber 
membrane 
bioreactor 
Low shear stress, better 
mimics cellular 
microenvironment. 
Difficult to scale up and the 
culture environment is 
inhomogeneous due to the 
nutrient and oxygen gradient. 
Difficult to monitor and sample 
cells. 
159 
Adherent Immobilized cells in 
3D scaffolds: Fixed 
bed, fluidized bed, 
fibrous bed 
Provide 3D 
microenvironment; allow cell 
spatial organization; regulate 
proliferation, differentiation 
and tissue formation. 
Difficult to harvest cells. Hard 
to visualize cells. 
78,160,161
 
Adherent Rotary cell culture 
system (RCCS) 
Low shear stress; good mass 
transfer; controlled 
oxygenation. 
Limited in size; hard to scale 
up; may not be able to produce 












Figure 2-3: Different culture methods for reactor culture. A) Cytodex 1 microcarriers with cells adherent 
to surface. B) Randomized cellulosic fiber matrix with cells on it. Cells stained with phalloidin green for 
imaging purposes. Scale bars are 100 microns 
  
A B 






Figure 2-4: Flow chart of process for whole cell therapy. Upstream processes involve the culture of the 
cells, and downstream is comprised of steps to increase purity of the resulting therapeutic. 
  






Figure 2-5: Lung on a chip. Developed for testing effects safety and efficacy of drugs on lung cells in vitro 
accurately. Developed by Wyss Institute for Biologically inspired Engineering and Harvard 
University.163This technology can be used in conjunction with bioproduced human stem cells, providing 
effective tissue modeling of both normal and potentially diseases tissues and the effects drugs can have on 
them. 




3 POLYMERS AND TREATMENTS 
3.1 ABSTRACT 
In order to reach clinically relevant numbers of hMSCs for stem cell based therapies, 
culture techniques must be used. To achieve this, fiber matrices and 3D printed polymers 
have been tested. In this work we test stem cell adhesion and growth to PE, silk, and 
cellulosic fibers, as well as PETG, T-PU, and PLA 3D printable polymers for used in a 
novel 3D bioreactor. Cellulosic fibers supported cell growth, but cells tended to form 
undesirable clusters. Gelatinized PLA showed the best cell adhesion and proliferation, 
forming monolayers akin to culture on 2D tissue culture dishes. hMSCs were easily 
removed and maintained their biomarker phenotype after seven days of culture. 
3.2 BACKGROUND AND INTRODUCTION 
Mesenchymal stem cells (MSCs) are promising candidates for therapies in the field of 
regenerative medicine. They have the ability to differentiate into mesoderm derived cell 
types including osteocytes, chondrocytes, adipocytes, and myocytes.1 They are described 
as fibrotic and are anchorage dependent cells.2 Factors such as topology and surface 
chemistry have been proven to affect the potency of hMSCs.3 As such, proper culture is 
heavily reliant on the choice of substrate the cell is grown on.  
Softer polymers and blends have been shown to induce hMSCs to a chondrocyte or 
adipocyte fate.4 Harder substrates have shown to promote cell elongation and osteocyte 
differentiation.5–7 This is thought to be because cartilage has a relatively pliant ECM, 




whereas cancellous bone is comparatively stiffer. This is due in part to their ability to test 
the substrate on which they reside, contracting to determine the stiffness of the ECM.8 
The cells are therefore fated to become the cells which reside in that level of rigidity.  
Researchers in polymer sciences have found that much of cell-substrate binding is 
through integrin mediated adhesion.9,10 The Integrin receptors on the surface of the 
hMSC recognize certain residues in the extracellular matrix proteins, leading to cell 
adhesion.11 The recognition and binding to basal membrane proteins such as collagen, 
laminin, and fibronectin are also through integrin binding. The selectivity of the integrin 
receptor comes from two subunits which form a dimer, and can vary widely based on the 
subunits combined. For example, B1 and A2 dimers selectively recognize DGEA 
residues of various collagens and laminin, while B3 AV has been shown to bind RGD 
sequences of vitronectin, fibrogen, Von Willebrand factor, thrombospondin, fibronectin, 
osteopontin, and collagen.11 
hMSCs also rely on cadherin to maintain stemness.12 N-cadherin is involved in cell 
migration and wound healing, and is an important protein in connective tissues.13,14 
Cadherin is mainly found in cell junctions, binding cells together in tissues.15 it is through 
the combination of cadherin and integrin that cells adhere, grow, and proliferate, making 
surface chemistry very important in the culture of sensitive cells such as hMSCs.15  
Another method of cell adhesion is through exposed hydroxyl groups.16 This is important 
for cell adhesion to plastics, a defining characteristic of MSCs.17 Interestingly, carboxyl 
groups inhibit cell adhesion.18 Using hydroxyl groups is a good way of reducing the cell 
culture reliance on xeno-sourced products, easing regulatory concerns for cell based 
products. Secondary to exposing hydroxyl groups, synthetic polymers like poly-D-lysine 




can be bound to plasma treated surfaces to further enhance cell adhesion.19 This is a 
means of treating plastics and polymers, therefore, plasma treatment and subsequent 
coating has its usefulness in polymer-based 3D scaffolds.20,21 
Scaffolds are used when growing cells in 3D cultures. This can be used to both increase 
usable surface area and to culture cells into a desired shape. The two main 3D culture 
methods are either hydrogel based or hard material support based. Hydrogels are 
polymers which swell with water.22 There are both natural ECM based hydrogels and 
fully synthetic hydrogels. Both scaffolds and hydrogels are common methods of culturing 
cells in 3D. Culturing cells in 3D has shown to increase cell-cell connections, mimicking 
natural environments.23 This increase in cell communication has also been linked to 
maintaining the stemness of mesenchymal stem cells.12 One way to orient and increase 
surface area in such hydrogels and rigid polymer scaffolds is through 3D printing. 
3D printing has proven to be a valuable tool in cell culture, specifically in regenerative 
medicine and stem cell culture.24 Scientist have been able to regrow bone in sheep using 
FDM 3D printing of Polybutylene Terephthalate for MSC growth and differentiation.25 
Other common 3D printing thermoplastics used in cell culture are Poly Lactic Acid 
(PLA), Polycaprolactone (PCL), and Polyethylene Terephthalate Glycol (PETG).26–29 3D 
printing of hydrogels has also proven useful for hindering hMSC mobility and attrition, 
which has been hypothesized to decrease effectiveness of hMSC therapies.30 Another 
feature of 3D printing is that the shape of the overall scaffold can be tailored to the 
intended therapy. 
In this work we investigate the effectiveness of various polymers on hMSC growth. 
Because of the significant increase in surface area, as well as rigidity desired in potential 




hMSC scaffolds, we focused on both fibers and hard polymers. Cellulosic, silk, 
polyethylene, and various polymers used in 3D printing were tested to see if they would 
support hMSC culture. Simple surface treatment of PLA was also tested as a means of 
increasing cell adhesion. The intention was to see which polymer best sustained hMSC 
culture to use in a scale-down model of the Express bioreactor from Sepragen 
Corporation (Hayward, CA). 
3.3 MATERIALS AND METHODS 
 Cell culture 
3.3.1.1 BEND3 Culture 
Murine BEND3 brain endothelial cells were used for cell culture feasibility studies. They 
were cultured as per ATCC recommendations. Cells were seeded at 5,000 cells/cm2 for 
culture propagation. Media was a high glucose DMED base containing sodium pyruvate 
(GIBCO 11995065), supplemented with 10% FBS (ATCC 30-2021) and 1% penicillin-
streptomycin (ATCC 30-2300). Cells were passaged using 0.25% Trypsin and 0.53 mM 
EDTA solution (ATCC 30-2101). Cells were fed on day 3 and passaged on day 6 or 
when confluency reached 90%. Experiments were conducted between passage 5 and 30. 
3.3.1.2 hMSC Culture 
hMSCs were cultured according to guidelines provided from ATCC. Briefly, cells were 
cultured in hMSC media (ATCC PCS-500-030) supplemented with the bone marrow 
derived hMSC bullet kit (ATCC PCS-500-041) at 37°C and 5% CO2. A ¾ media 
exchange was performed on day 3, and cells were passaged at 80-90% confluency, 




usually on day 6. Cells were lifted using 3.5mL of 0.25% Trypsin and 0.53 mM EDTA 
solution (ATCC 30-2101) for regular passaging of T-75 flasks, and cells were re-plated at 
5,000 cells cm-2. Working cell bank was created from pass 4 hMSCs and stored in liquid 
nitrogen. Experiments using hMSCs were conducted on cells between passage 5 and 9.  
 Cellulosic scaffold 
Cellulosic samples were provided by Sepragen Corporation (Hayward, CA). This 
scaffold material is treated to promote cell adhesion and is currently used in their Express 
bioreactor line. For test cultures 1cm2 swatches were cut to fit into 12 well plates. 
Seeding experiments varied, but included static adhesion, rocking, and gelatin vs 
untreated samples. For static seeding a rough estimate of surface area was taken using 
porosity found using FIJI. The appropriate cell number was suspended in the volume 
necessary to wet the swatch and set overnight in the incubator. The well was then brought 
to appropriate volume. Cells were then cultured out for seven days. 
For rocking the cells were place in total well volume and the swatch was place with the 
cell laden media. The culture plate was then place on an oscillating rocker (Adams 
Nutator Model 1105) overnight in 37°C and 5% CO2 incubator.  
Cellulosic scaffolds were gelatinized by placing swatches in filtered and autoclave-
sterilized 0.1% (W/V) porcine gelatin (Fisher 9000-70-8) solution in MQ water. The 
submerged swatches were placed at 37°C for 30 minutes. Swatches were then washed 
with PBS and cell inoculum was added to the wells or directly to the scaffold depending 
on adhesion and culture study. 




For bioreactor studies a swatch of cellulosic was cut, sterilized and gelatinized according 
to previous methods. A 50mL conical tube cap was fitted with four ports. One extended 
to the middle of the tube, one to the bottom, and two had no extensions. The two without 
any internal attachments were for gas exchange. 106 hMSCs were suspended into 15mL 
of media and added to the reactor. Seeding circulation started at 5mL min-1 for one hour, 
then was set to 2.5mL/min for one hour, then brought down to 1.5mL min-1. Media 
circulation was tested between 1.0-2.0mL min-1 for the remainder of the seven days. 
 Silk and polyester  
100% Silk fabric purchased from fabric store was cleaned with hot water and soap. 
Swatches were cut and autoclave sterilized for 15 minutes at 112°C. Four swatches of 
silk fibers were rewetted in PBS and placed into well plates. Two control wells, two 
ungelatinized swatches, and two gelled swatches were seeded at a density of 5,000 cells 
cm-2 based on well area. At day seven cells were fixed and stained for visualization using 
fluorescent microscopy. 
Polyester was sterilized and prepared in the same way as silk fibroin swatches. After a 15 
minute autoclave cycle the fabric shape and texture was altered, but still stable enough 
for culture. Cells were plated at 5,000 cells cm-2 and cultured for seven days. After which 
cells were stained and imaged by fluorescent microscopy. 
 PLA and plasma etching 
PLA scaffolds were 3D printed using a PrintrBot Simple Metal (Printrbot) and Cura 3.2.1 
slicing software. Translucent high temperature PLA (Protoplant) was used. PLA was 
printed at 212°C. PLA was autoclaved at 121°C for 15 minutes to both sterilize and heat 




treat the PLA. For plasma treatment, samples were first placed in plasma cleaner (Harrick 
Plasma, model PDC-32G) set on high for three minutes. Plasma was created under 
vacuum without addition of argon or oxygen. Samples were then wetted with MQ water 
and autoclave sterilized for 15 minutes before culture. 
 PETG and T-PU 
Polyethylene Terephthalate Glycol (PETG) (3D Solutech) was printed at 207°C. It was 
autoclave sterilized for 15 minutes at 121°C. Like the PLA, it was printed in both flat 
sheet and lattice form to test cell growth and adhesion. A comparison of gelatinized and 
control PET scaffolds was also performed. Thermoplastic Polyurethane (SainSmart) was 
printed at 200°C. The same wash and sterilization steps were followed to prepare 
Thermoplastic-Polyurethane (T-PU) as with PETG. These samples were not tested with 
plasma etching. 
 Drop test for measuring contact angle 
To measure contact angle, a drop test was performed on untreated and treated cell culture 
scaffold samples. A 2µL drop of MQ water was made using a micropipette, and the drop 
was slowly brought down to the surface being tested. The drop was allowed to contact the 
surface and stabilize for 10 seconds. A photograph was taken and uploaded to FIJI 
(ImageJ) for analysis. The analysis package used was drop_snake.31 To do this the 
photograph was first converted to 8-bit black and white. Then using the software package 
the circumference was drawn, and vertexes of the angles noted. The software is then able 
to simulate the drop and calculate the contact angle of the drop. Hydrophobic surfaces are 
defined as having a contact angle greater than 90 degrees, and hydrophilic angles are less 




than 90 degrees. Each treatment was measured three times and an average contact angle 
was calculated. 
 SEM imaging 
PLA matrices were washed and prepared for electron microscopy. Using conductive 
double-sided copper tape samples were stuck to 1/2in slotted stages (TED PELLA 
16111). Samples were imaged at 2kV using Hitachi SU-70 scanning electron microscope.  
 Confocal imaging 
Cells were grown on various scaffolds and washed using Ca++ and Mg++ PBS. The cells 
were then fixed in place with 4% PFA for 15 minutes and washed again with PBS. 
Permeabilization was performed using 1% (W/V) Triton-X 100 in PBS for 30 minutes at 
37°C. Cells were then washed and placed in 1% (W/V) Bovine Serum Albumin (BSA) 
and 0.1% (W/V) Triton-X 100 in PBS for 1 hour at room temperature. Cells were then 
stained with 1 drop per mL Phalloidin green (Invitrogen) and 2.3nM DAPI. To visualize 
viable cells on the matrix the same wash steps were followed, but cells were not fixed nor 
permeabilized. Calcein-AM (ab141420) was used instead of Phalloidin. 1μL of 1mM of 
Calcein solution was added to 1mL of Ca++ and Mg++ PBS and cells were incubated for 
10 minutes at 37°C. Since Calcein-AM must be processed to fluoresce, no subsequent 
washing was performed.  
 Flow Cytometry 
hMSCs were cultured in experimental conditions and lifted with TrypLE-Express to 
preserve cell surface receptors. Cells were first washed with PBS, then placed in TyrpLE 
for 15 minutes. After neutralization cells were fixed in 4% paraformaldehyde (PFA) for 




15 minutes, washed twice, and blocked for 1 hour at room temperature. Blocking solution 
consisted of 1% (W/V) BSA (LONZA) and 0.1 % (W/V) Triton-X 100 in PBS. Cells 
were stained for the positive markers CD105 (Invitrogen MHCD10520) and CD73 
(Abcam ab157335) and were negative for CD14 (Abcam ab91146) and CD19 (Abcam 
ab25510) at 1μL per 500,000 cells in 500μL following recommendations. Samples were 
then run at medium speed (35μl min-1) on a BD Accuri C6 flow cytometer and analyzed 
using FlowJo V10 (Ashland, OR). Unstained controls were used to gate cells. 
Compensation was done through FlowJo and Fluorescence Minus One (FMO) 
techniques. Initial bioreactor studies were done using only CD105 and CD34. 
3.4 RESULTS 
 Cultures 
Cellulosic scaffold had very poor cell adhesion when un-gelatinized both with Bend3 
(Figure 3-1 A) and with hMSCs (Figure 3-2 A). Without gelatin, cells were very 
spherical and pseudopodia can be seen unattached to cellulosic material. When 
gelatinized many more Bend3 cells can be seen on the cellulosic fibers (Figure 3-1 B). 
Furthermore, cell morphology is more similar to normal polystyrene T-flask culture, 
showing cell elongation running along the fiber (Figure 3-2 B).  
Silk scaffolds showed some cell retention (Figure 3-3 A) but compared to cellulosic and 
PLA it performed very poorly. However, cells imaged on silk fabric showed some 
colonies forming by day seven. Because of poor growth and adhesion, it was not possible 
to run cells though flow to analyze resulting cells. 




Polyethylene cultures visually show increased cell adhesion compared to silk fibers 
(Figure 3-3 B). However, when cells were lifted from scaffold and analyzed via two 
marker flow cytometry it was found that not only were there very few cells to count, but 
that cells did not maintain their CD105 marker expression indicating differentiation 
(Figure 3-4). 
Contact angles were measured via software according to Figure 3-5. The only sample that 
showed statistically significant difference to other conditions tested was untreated PLA 
(p<0.05). Plasma treated PLA similar hydrophilicity (p>0.05) to PS dishes (Figure 3-6). 
Gelatin also resulted in similar contact angles as PS and plasma treated PLA (p>0.05). 
Because plasma treatment eliminates the use of animal derived products, we initially 
tested cell culture on plasma treated PLA prints. Cell adhesion and morphology of 
densely seeded hMSCs on day one appear very similar to polystyrene culture dishes 
(Figure 3-7 A). However, by day two very few cells were seen on the scaffold, and 
colonies were very sparse (Figure 3-7 B). Values are not reported, but when lifted cell 
number were far lower than expected. Gelatin coated PLA showed the same contact angle 
as control PS dishes. Because of this, gelatin treatment was used for all subsequent PLA 
cultures. Moreover, flow cytometry data showed that the cells that were lifted from 
gelatin coated PLA on day seven retained proper four marker cell surface profile (Figure 
3-8). 
Cells did not readily adhere to TPU, even when gelatinized. Its opacity also made it 
difficult to image. PETG scaffolds deformed in the autoclave and poor cell growth was 
seen. Because of this these scaffolds were omitted. 




 PLA lattice 
Though testing of extrusion rates and speeds of the printer it was determined that between 
20 and 30mm s-1 using 0.15mm layer height resulted in the best, most homogenous 
geometry (Figure 3-9). There were however some abnormalities in the print. At almost all 
tested printer speeds there is still a small extra filament crossing the lumen of the channel 
(Figure 3-9 A-D). As this would increase surface area and was rather predictable in 
printing it was not worrisome. Layer height and extrusion percent were also tested, and it 
was found that 0.15mm and 100% extrusion resulted in the most homogenous and 
optically clear PLA structures (Figure 3-10). To see surface nanotopology the lattices 
were imaged using SEM, which showed very similar surface modalities to polystyrene 
(Figure 3-11). However, after optimization it was found that the printer speed could be 
increased to 80mm s-1 at a layer height of 0.2mm. This was accomplished by slicing the 
object at 50% infill and printing at zero wall thickness. The resulting print was a grid 
pattern infill with very homogenous pores and no hanging extrusions or burrs (Figure 
3-12).  
 Bioreactor Culture 
Reactor cultures were step up and run according to Figure 3-13 A. The system is made of 
a polycarbonate tube and two stainless steel caps on either end to make a chamber. There 
is a small pass-through port capped with silicone on the front of the reactor, and four 
Luer lock ports on the top. Two ports handle liquids, while the remaining two are 0.2µm 
filter capped for gas exchange. Media is circulated by an external peristaltic pump and 
gas is overlaid into the chamber at a flow rate of 0.01VVM. Both cellulosic and gelatin 
coated PLA were tested in the system. Figure 3-13 B shows how the cellulosic swatch 




was wrapped around a 15mL conical tube suspended in the center of the reactor. The 
growth area (PLA or cellulosic) is suspended to allow media to flow through it, creating a 
much smaller boundary layer of media above the cells. The media collects at the bottom 
and stays in the chamber to maintain humidity, where a drop tube from one of the top 
Luer lock ports can then continue recirculation via external peristaltic pump. Initial flow 
rates were 1mL min-1 and optimizing seeding procedure led to the largest increase in cells 
gained. Recirculating cell suspension resulted in little to no cell yields on day seven. 
Cellulosic based cultures supported cell adhesion (Figure 3-14 A) and growth, resulting 
in cell clusters within the fiber matrix (Figure 3-14 B). However, significant particulate 
collection at the base of the bioreactor reservoir, increasing particulates in solution and in 
turn making flow cytometry to quantify cell purity very difficult.  
PLA reactor cultures performed better than cellulosic matrix. However, a different 
seeding strategy had to be adopted. To properly seed the lattice cells were suspended in 
small volumes and injected above the lattice. The cells in media were allowed one hour to 
settle and adhere without the reactor recirculating any media. Cells were easily lifted and 
characterized via four marker flow cytometry, which showed that cells maintained their 
stem cell phenotype (Figure 3-15). Dot-plot density also showed that much more cells 
had been harvested than previous runs. Confocal images using Calcein viability staining 
showed hMSCs adherent onto the PLA cross lattice in confluent layers of cells after 
seven days in culture (Figure 3-16). 
Comparing PLA, PS and Cytodex we saw that cellulosic showed the best doubling time (  




Table 3-1). It was found that the substrates and samples tested hade relatively similar 
doubling times after seven days in culture. The substrate that showed the most doublings 
was PLA in static culture, and the poorest performing was actually ungelatinized static 
PS. Unfortunately, this was not done in triplicate, and as such we could not calculate 
statistical difference.  
3.5 DISCUSSION 
TPU was optically opaque, making any cell visualization impossible. As such it was not 
pursued as a cell scaffold. Cell monitoring is necessary in reactor cultures, and since cells 
could not be easily seen on the substrate it was not used in bioreactor culture. It would be 
interesting to use optically clearer filament and test cells for differentiation. As softer 
materials have shown to induce chondrocyte differentiation, it may be a new dynamic 
culture method to differentiate hMSCs to chondrocytes in-situ.4,7 This is especially true 
as polyurethane has been used in cartilage tissue engineering previously.32 
PLA plasma treatment resulted in increased cell attachment, but also apoptosis. After 
treatment the polymer most likely retained reactive oxygen species on its surface, which 
while charging the surface and increasing wettability and adhesion, it also increased cell 
death. However, others have successfully used plasma to increase cell adhesion and have 
no effect on cell proliferation compared to untreated samples.20 One difference was that 
the samples used in that study were ethylene oxide sterilized for four days post plasma 
treatment. What may be necessary for future plasma treatment steps is a PBS soak and 
time for surface species to dissipate. If cell death due to reactive species was mitigated 




this would be a very scalable and cost-effective means of making a Xeno-free treatment 
for 3D cell culture. 
Cellulosic scaffolds showed initial promise. Cellulosic is biocompatible and has already 
been tested as a drug delivery vehicle.33–35 3D printed cellulosic scaffolds have been 
proven to support cell growth.36 However, in this case the cellulose may have been acting 
as a filter, catching cells as they passed through the material rather than promoting 
adhesion. Initially this was desirable, as cells would become stuck against the lattice 
through fluid movement, increasing final yield. However, untreated cellulosic did not 
show elongated cells indicative of cell adhesion, and thus cells did not proliferate. When 
cellulose was gelatinized the cells tended to grow in clusters, which has been shown to 
induce differentiation.37 It has also been shown that aggregate culture decrease overall 
proliferation in MSCs, and as such cellulosic material was not pursued further.38–40 
Thus, PLA was chosen for its cell adhesion, biodegradability, rigidity, and ease of 
manufacturing into 3D lattices.41,42 Cells cultured for seven days retained their biomarker 
profile even on PLA in a dynamic culture environment. The decrease in doublings from 
static to dynamic culture is best explained by initial cell seating. Untreated PLA has a 
very high contact angle, and in dynamic culture would not catch the cells very well. In 
static culture though the cells would settle due to gravity, thus the initial seed would be 
far more efficient. 
Even with this simplified small-scale reactor there were many problems. An Ishikawa 
diagram was used to highlight problem areas and possible causes during bioreactor 
culture (Figure 3-17). From this the main issues we saw that fittings were the main source 
of leakage and contamination. Once identified, the nylon fittings were exchanged for 




polycarbonate Luer lock and stainless-steel barbed fittings, which stopped contamination 
and leaking problems. 
3.6 CONCLUSION 
Gelatinized PLA worked the best of the materials tested. Plasma treatment of the PLA led 
to increased hydrophilicity and better wetting. Initially cell cultures plated on plasma 
treated PLA showed better adhesion, however by day three cells were very sparse. This 
may be due to residual reactive species on the surface of the PLA. Gelatinized cellulosic 
also showed promise in cell culture, as cells were seeded in single cell suspension and 
colonies were observed by day seven. However, cell harvest was very sparse and 
contained degraded fragments of the matrix. Here we have shown that gelatinized 3D 
PLA scaffolds can support hMSC growth in a dynamic environment. Cells lifted also 
retained their biomarker profile. 
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Figure 3-1: Bend3 Cultures on A) untreated control and B) gelatinized cellulosic material in static culture 
conditions. Cells were seeded statically by overlaying cell containing media onto scaffolds and culturing 
for 24 hours. Green is actin staining. 
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Figure 3-2: hMSCs culture on cellulosic fibers after 24 hours. A) Single cell on ungelatinized control and 
B) Gelatin coated cellulosic material in seeded statically. Green is actin and blue are the nuclei. Nuclear 
staining was not seen in A because of issues with UV laser on the confocal. 
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Figure 3-3: hMSCs grown on other fiber lattices for seven days. A) Gelatin coated silk fibroin and B) 
gelatin coated Polyethylene. Green is actin and blue are the nuclei. 
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Figure 3-4: Flow cytometry of hMSCs grown for seven days on Polyethylene in static culture. Very few 
cells recovered from PE fiber swatch, so very few cells were tested for flow cytometry. 
  






Figure 3-5: Contact angle measurements of PLA. Vertical lines overlaid onto picture of 2µl droplet created 
using drop_snake software. The circumference of the drop is outlined through the software, which then 
calculates the angle from normal. A) Untreated PLA from printer. B) Three-minute plasma treated PLA. 
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Figure 3-6: Contact angles of plastics and treatments calculated via the drop_snake method in FIJI. 
  






Figure 3-7: hMSCs statically seeded onto plasma treated PLA 2D sheets. A) hMSCs show adhesion to PLA 
surface after 24 hours. B) After 48 hours hMSCs appear more sparse on the surface of the plasma treated 
PLA. Green is actin and blue are the nuclei. 
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Figure 3-8: Static culture of hMSCs on PLA static controls. Cells were fixed, blocked, and stained for 
surface markers CD105 CD73 CD19 and CD14. Rows correspond to two different samples. 
  






Figure 3-9: Printer speed effect on 3D printed PLA lattice pore geometry. Scale bars are 200 microns and 
values above images are the printer speed in mm s-1. Viewed from the side (XZ). 
  






Figure 3-10: Printer setup. Extrusion percent vs layer height. Viewed from the side (XZ). Scale bars are 
200 microns. 
  






Figure 3-11: SEM images of Polystyrene and PLA lattice. Top row shows ungelatinized controls and 
bottom are gelatin treated. A) Low magnification image of the side of ungelatinized PLA lattice. B) High 
magnification of ungelatinized PLA. C) Ungelatinized PS control culture dish at high magnification. D) 
Low magnification of gelatinized PLA lattice from the top view. E) High magnification image of gelatinized 
PLA. F) High magnification of gelatinized polystyrene culture plate control. 
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Figure 3-12: Improved printing of lattice. By altering G-code 3D printer more homogenous prints were 











Figure 3-13: Bioreactor design using cellulosic scaffold. A) Cartoon diagram showing reactor, reservoir, 
peristaltic pump and air pump. B) Assembled cellulosic scaffold-based reactor. Reactor comprised of two 
316 stainless steel capping a polycarbonate chamber sealed with high temperature silicone O-rings sealed. 
Four threaded Luer loc connectors allow media circulation and gas exchange. 
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Figure 3-14: hMSCs cultured for seven days on gelatin treated cellulosic scaffold in dynamic bioreactor 
culture. A) Low magnification picture of seeded lattice. B) High magnification of cell cluster grown from 
single cell. Green is actin and blue are the nuclei. 
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Figure 3-15: F Flowcytometry of hMSCs from PLA Bioreactor lifted on day 7. Cells were cultured in 
normoxic conditions in the PLA lattice for seven days prior to lifting and staining. Cells were fixed, blocked 
and stained for CD105 and CD34. Each row is one sample. 





Figure 3-16: Cells on improved PLA Lattice. hMSCs were cultured for seven days on the PLA scaffolds in 
the bioreactor, then stained for viability.  Green is Calcein viability staining. 
  




Table 3-1 Doubling statistics of hMSCs on various culture substrates 
Condition Doublings Doubling Time (hr) µ (1/hr) Fold Increase 
PS Static 1.37 124 0.006 2.93 
PS Static 0.1% 
Gelatin 1.56 109 0.006 - 
Cellulosic Matrix 1.81 93 0.007 3.00 
PLA Static 2.08 80 0.009 2.69 
PLA Dynamic 1.42 120 0.006 2.72 
 
  























4 STEM CELL REACTOR CULTURE 
4.1 ABSTRACT 
Bone marrow derived human Mesenchymal Stem Cell (hMSC) harvest is invasive, 
painful, and expensive, which makes it difficult to supply the enormous amount of pure 
hMSCs needed for future allogenic therapies. Because of this, a robust method of scaled 
bioreactor culture must be designed to supply the need for high purity, high density 
hMSC yields. Here we test a scaled down model of a novel bioreactor consisting of a 3D 
printed PLA lattice matrix suspended outside of its culture media. The growth matrix is a 
uniform and replicable biocompatible 3D printed polylactic acid lattice matrix, which 
enables homogenous cell culture in three dimensions. The system tested resulted in 
comparable stem cell yields to other cell culture systems using bone marrow derived 
hMSCs, while maintaining high purity (>98% expression of combined positive markers), 
high viability (96.54% ±2.82), and differentiation ability into functional cell types.  
4.2 INTRODUCTION 
Stem cells are a major component of regenerative medicine that show promise of curing 
chronic diseases and organ regeneration.1 What defines this cell type and cements its 
usefulness in regenerative therapies is that stem cells can both self-renew and 
differentiate into functional cell types. Stem cells are generally classified into three main 
types: embryonic, induced pluripotent, and adult stem cells. Human Mesenchymal Stem 
Cells (hMSCs) are a type of adult multipotent stem cell which can differentiate into many 




useful cell types for regenerative medicine including osteocytes, adipocytes, 
chondrocytes, myocytes, and cardiomyocytes.2 hMSCs have been widely researched, and 
hMSC derived stem cell therapies are currently under clinical trials for cardiovascular, 
neurologic, bone and cartilage, lung, kidney, liver, and autoimmune diseases.3 They also 
show immunotolerant and immunomodulatory properties in allogenic transplants.2,4 
However, bone marrow derived hMSC harvest is invasive, relatively low yield, and 
painful, making allogenic therapies difficult and expensive.5  
The challenges of creating therapeutic dosages lies in both the number of cells needed for 
a successful therapy, and the sensitive nature of hMSCs. It is estimated that a therapeutic 
dose of 106 to 15x106 stem cells per kilogram are needed to treat diseases such as diabetes 
and myocardial infarction.6–9 These high estimates are due to apoptosis, unwanted 
differentiation, and cell attrition after implantation.10–12 Furthermore, dosing strategies 
may require multiple doses, further inflating estimates. This may explain the lack of 
phase three clinical trials.12 Scaled bioproduction of hMSCs is one way to supply such a 
large number of stem cells. However, conventional scalable culture procedures are 
difficult since hMSCs are anchorage dependent and sensitive to mechanical and chemical 
stresses.13–15 Exposure to high shear stress, media gradients, unfavorable surface 
treatments, improper cytokine mixtures, or nanotopologies can lead to differentiation and 
apoptosis.15–18 In scalable systems aimed at producing hMSCs, any of these factors would 
decrease purity and result in lost yield. Per the International Society for Cellular Therapy 
(ISCT), tested stem cell populations must be greater than 95% positive for CD105, CD73, 
and CD90, while being negative (less than 2% positive) for CD45, CD34, CD19 and 
CD14 via flow cytometry in order to be considered pure.19 hMSCs must also maintain 




their ability to differentiation into adipocytes, chondrocytes, and osteocytes. Any 
decrease in purity would increase downstream purification, further decreasing cell yield 
and increasing cost.  
To meet the high hMSC yields and purities needed, specialized bioreactors have been 
developed to optimize culture conditions. Systems used for stem cell bioprocessing vary 
but fall into three general categories: stacked two-dimensional surfaces, microcarrier or 
aggregate based, and fixed bed reactors. A brief comparison of various adherent cell 
culture methods can be seen in Table 4-1. Stacked systems such as the Xpansion 
Multiplate parallel plate bioreactor (Pall) combine multiple 2D culture surfaces into one 
unit analogous to multiple T-flasks.20 Media can then be flowed laterally across the cells 
to supply nutrients and exchange gases. Though the most similar to flask culture, it is 
difficult to visualize for in-process tests and may produce more shear than desired.21,22 
Microcarriers have been used for 3D suspension culture of adherent stem cells. They can 
be made from a variety of materials including inorganic plastics, sugars, and digestible 
materials.12,23,24 The microcarriers are suspended via mechanical mixing while cells 
adhere to the surface of the microcarriers. Because mixing is usually impeller driven, 
cells can be exposed to high shear.22,25 Using microcarriers also involves more 
downstream processes to purify the cells from the carriers, and lifting procedures can 
involve multiple steps.7,26 Fixed bed reactors use fiber mesh as their culture surface and 
provide nutrient and gas exchange by flowing media through the mesh. Examples of this 
type of bioreactor include the iCELLis (Pall), hollow fiber membranes such as Quantum 
(Terumo BCT), and the Express (Sepragen) reactor. Like the multiplate systems 




mentioned, it is difficult to visualize the cells during culture. A summary of cell yield and 
reported values of various cell culture systems can be seen in Table 4-2. 
Here we investigate a scaled down model of the Express bioreactor. The variant tested 
works much like the parent reactor, using gravity and wicking of media to provide 
nutrients and gas exchange to a growth matrix suspended above culture media. This 
geometry and media circulation strategy results in low shear fluid movement. Instead of 
cellulosic, a 3D printed lattice made of Polylactic Acid (PLA) lattice matrix is suspended 
outside of the liquid media, providing a biocompatible culture surface with similar 
stiffness to plastics used in conventional culture. Small sampling shelves are integrated 
into the lattice matrix, which can be easily removed for cell sampling and imaging. By 
combining this dynamic culture method with a hypoxic conditioning, stem cell 
proliferation was significantly increased while maintaining stem cell biomarker 
expression. 
4.3 METHODS 
 Stem cell culture 
hMSCs were cultured according to guidelines provided from American Type Culture 
Collection (ATCC). Briefly, cells were cultured in hMSC media (ATCC PCS-500-030) 
supplemented with the bone marrow derived hMSC bullet kit (ATCC PCS-500-041) at 
37°C and 5% CO2 on T-75 treated tissue culture flasks. A ¾ media exchange was 
performed on day 3, and cells were passaged at 80% confluency, usually on days 6 or 7. 
Cells were lifted using 3.5mL of 0.25% trypsin and 0.53 mM EDTA solution (ATCC 30-
2101) for regular passaging of T-75 flasks, and cells were re-plated at 5,000 cm-2. Cell 




pelleting was performed by centrifugation at 270 x g for 5 minutes. Working cell bank 
was created from passage 4 hMSCs and stored in liquid nitrogen. Experiments using 
hMSCs were conducted on cells between passage 5 and 9. Specific growth rate and 
doubling time were calculated to compare culture success. 







Equation 4-1: Doubling time. Where Td is the doubling time in days, q2 is the final cell count, and q1 is the 








Equation 4-2: Specific growth rate. Where μ is the specific growth rate in hours, q2 is the final cell yield 
and q1 is the initial cell seeding quantity. 
 Oxygen tension studies 
To induce low oxygen states, cells were placed in a hypoxia chamber (billups-
rothenberg) and gas flushed for 6 minutes with the regulator set at 5PSI and 10L min-1. 
Gas composition varied but was mixed based on PSI. For reactor cultures the mixed 
gasses were introduced at 100mL min-1 for 5 minutes to exchange the head space and 
oxygen from the media. At first tri-gas mixture including 5% CO2 was used, but hMSCs 
preferred basic conditions and as such CO2was excluded from later bioreactor runs with 
negligible impact on yield and purity. 
 Reactor construction 
The chamber of the reactor is made of a 9cm long polycarbonate tube with an ID of 
2.25in and an OD of 2.50in. Four 316 stainless steel barbed hose adapters are tapped into 




the top of the polycarbonate, two for media circulation and two for gas exchange through 
0.2µm filters. Size 14 silicone hose was used for main liquid handing loop, with a Tygon 
Pharmed section for peristaltic pumping. The headplate and backplate are made of 316 
Stainless steel. The interior reactor components include the 3D printed matrix, which is 
suspended out of the media using two brackets. Media pumped to the top of the lattice is 
perfused through the lattice design via gravity, providing gas exchange and nutrients to 
the cells. Gas control is highly tunable, as there is less liquid for gas to diffuse through to 
be available to the cells. The front plate of steel has a pass-through port for access to 
removable sampling scaffolds to monitor cell confluency. Both the lattice matrix and the 
holding parts were printed from PLA. Minimum and maximum working volumes used 
were 20 and 30mL. 
 Lattice design and bioreactor culture 
PLA matrices were 3D printed using a PrintrBot Simple printer and Cura 3D (V3.2.1) 
printing software. A 0.4mm nozzle diameter was used. PLA was chosen as it has been 
used for cell culture, is both biocompatible and biodegradable, and is a thermoplastic 
commonly used in 3D printing.27,28 The lattice is constructed in such a way that the 
smallest features are printable with a conventional 3D printer, and allow ample space for 
cells to culture into monolayers. For this extruder the lower limit of resolution was 400 
microns in the XY plane. The lumen between fibers was made to be the same width as 
the fiber itself. Also included into the design are two inserts for non-destructive means of 
visualization of cell confluence and viability via calcein staining. To sterilize parts before 
culture, the matrix and supports are assembled and placed into reactor and steam 
sterilized at 121°C for 15 minutes under a dry cycle. After sterilization the matrix is 




washed and wetted with filtered and autoclave-sterilized 1x PBS (VWR VE404) and 
gelatinized with filtered and autoclave-sterilized 0.1% (W/V) gelatin (Fisher 9000-70-8) 
in MQ water for 45 minutes at 37°C, or overnight at 4°C. The matrix is then rinsed with 
PBS to remove excess gelatin, and cells are seeded at 2,500 cells cm-2. Approximate 
surface area was calculated using Solidworks (Waltham, MA) analysis function. To allow 
cells to adhere only in the lattice the desired number of cells were resuspended first in a 
total of 2mL, as this volume was found to be the holding volume of the matrix. Cells 
were allowed to settle in the matrix for 45 minutes before starting the recirculation loop. 
Recirculation was run between 0.25mL min-1 and 0.5mL min-1. A range is noted because 
as the peristaltic tube relaxed during use, the peristaltic pump tended to speed up, slightly 
increasing the overall rate. This was the allowable flow rate range because it was the 
slowest rate that still allowed complete matrix wetting. A ¾ media exchange was 
performed on day 3, and cells were harvested on day 7 using a lifting cocktail comprised 
of a 2:1 mixture of Cell Dissociation Buffer (CDB) (Gibco 13151014) and TrypLE-
Express (Gibco 12604021). Lifting was accomplished by aspirating media out and 
cycling 10mL of PBS through system at 1ml min-1 to remove residual media. PBS was 
then aspirated and cell lifting cocktail was added. The reactor was then cycled at 0.25ml 
min-1 for 30 minutes, or later at 1.5mL min-1 for 15 minutes. Viability and cell counting 
were performed using hemocytometer and trypan blue staining. 
 Microcarrier culture in spinner flask 
Cytodex-1 microcarriers were weighed and autoclaved at 121°C for 15 minutes. 
Microcarriers were then hydrated in hMSC media. Cells were seeded at 5,000 cells cm-2 
in 50mL of media in a 250mL spinner flask (Wheaton). For the first 24 hours, the spinner 




flask was set to 15RPM to allow hMSCs time to adhere to the microcarriers, after which 
agitation was increased to 30RPM and volume increased to 80mL. A ½ media change 
was performed on day 3. Samples were drawn each day and fixed in 4% 
paraformaldehyde (PFA) for 15 minutes. Cells were then prepared for cell counting via 
DRAQ5 (Abcam ab108410), staining in a 5mMol solution overnight. Samples were then 
washed twice with PBS, allowing microcarriers to gravity settle between washes. 
Samples were imaged on Leica SP5. The culture was run for a total of 7 days. On day 7 
media containing microcarriers was split into 50 falcon tubes and microcarriers allowed 
to settle for 20 minutes. Media was aspirated and microcarriers washed twice with PBS. 
When settled again, TryplE (Gibco 12604021) was added and mixture was put back into 
the incubator for one hour to lift cells for counting and characterization. 
 Confocal microscopy 
Cells were cultured on lattice matrices in the bioreactor for seven days. Cells were 
washed using Ca++ and Mg++ PBS and fixed in place with 4% PFA for 15 minutes and 
washed again with PBS. Permeabilization was performed using 1% (W/V) Triton-X 100 
in PBS for 30 minutes at 37°C. Cells were then washed and placed in 1% (W/V) Bovine 
Serum Albumin (BSA) and 0.1% (W/V) Triton-X 100 in PBS for one hour at room 
temperature. Cells were then stained for 30 minutes with 1 drop mL-1 Phalloidin green 
(Invitrogen) and 1µl mL-1 DRAQ 5 (Abcam) resulting in a 5mMol solution in the 
blocking solution. Cells were washed with Ca++ and Mg++ PBS and imaged on a Leica 
SP5 confocal microscope.  




 SEM imaging 
PLA matrices were washed and prepared for electron microscopy. Samples were stuck to 
0.5in slotted stages (TED PELLA 16111) using conductive double-sided copper tape. 
Samples were imaged at 2kV using Hitachi SU-70 scanning electron microscope. 
 Flow cytometry 
hMSCs were cultured in experimental conditions and lifted with a 2:1 mixture of Cell 
Dissociation Buffer (CDB) (Gibco 13151014) and TrypLE-Express (Gibco 12604021) 
lifting cocktail to preserve cell surface markers. Cells were washed in PBS and placed in 
lifting cocktail for 15 minutes. After neutralization with fresh media, cells were fixed in 
4% PFA for 15 minutes, washed twice with PBS, and blocked for 1 hour at room 
temperature. Blocking solution consisted of 1% (W/V) BSA (LONZA) and 0.1% (W/V) 
Triton-X 100 in PBS. Cells were stained for the positive markers CD105 (Invitrogen 
MHCD10520) and CD73 (Abcam ab157335) and were negative markers CD14 (Abcam 
ab91146) and CD19 (Abcam ab25510) at 1μL per 500,000 cells in 500μL following 
recommendations. Samples were then run at medium speed (35μl/min) on a BD Accuri 
C6 flow cytometer and analyzed using FlowJo (Ashland, OR). Unstained controls were 
used to gate cells. Fluorophore compensation was done through FlowJo and Fluorescence 
minus one (FMO) techniques. 
 hMSC Differentiation and staining 
For both adipocyte and osteocyte differentiation, hMSCs were seeded at 12,000 cells cm2 
and cultured for three days in hMSC media following ATCC Toolkit protocols. ATCC 
differentiation toolkits for Osteocyte (PCS-500-052) and Adipocyte (PCS-500-050) 




differentiation were used. On the third day media was completely exchanged. For 
Adipocyte differentiation a conditioning pre-differentiation media was used, and every 
third day a ½ media change was performed with Adipocyte maintenance media. 
Osteocyte differentiation did not require a conditioning media and was maintained with 
only osteocyte toolkit media. On day 20 cells were washed with calcium magnesium free 
PBS and fixed by 4% PFA at room temperature for 15 minutes. Cells were washed, 
stained following respective protocols explained below, washed with MQ water, and 
visualized on a phase contrast Olympus IX microscope. 
Chondrocyte induction was performed according to a combination of ATCC protocols 
and previous research. Briefly, hMSCs were lifted from reactor using lifting cocktail, and 
counted. Cells were resuspended in chondrocyte differentiation toolkit (ATCC PCS-500-
051) at 125,000 cells mL-1. 200µl of cell laden media was put into 15ml polypropylene 
falcon tubes and centrifuged at 270 x g for 5 minutes and placed into incubator without 
resuspending cell pellet. When placed into incubator the tops of the tubes were loosened 
to allow gas exchange. After 24 hours the pellet was gently suspended via pipetting. 
Media was changed every 3 days for 21 days total. On day 21 cell aggregates were sliced 
into 8µm thick samples using a HM 500 cryostat (Microm) and OTC compound (Tissue 
Tek 4583) and place onto glass slides. Samples were then stained and visualized on a 
phase contrast Olympus IX microscope.  
4.3.9.1 Oil red O  
Oil Red O was used to stain adipogenic differentiation of hMSCs. A working solution 
was prepared by mixing 3ml of Oil Red solution (#O-1391, Sigma) 2ml of MQ water 




immediately before. Cells were covered with oil red working solution and stained for 30 
minutes at room temperature. Cells were washed twice with MQ water and visualized. 
4.3.9.2 Alizarin red 
Alizarin Red stain was used to stain osteogenic differentiation of hMSCs. It arrived in 
working concentration at the proper pH, so no extra formulation was necessary. After 
fixation cells were washed twice with MQ water, then Alizarin red staining was overlaid 
onto the cells and left for 15 minutes. Cells were then washed three times with MQ Water 
and visualized. 
4.3.9.3 Alcian blue 
Alcian blue was used to stain for chondrogenic differentiation of hMSCs. After cryostat 
slicing the samples were washed in Ca++ Mg++ PBS to preserve attachments while 
removing OTC compound, and fixed for 15 minutes in 4% PFA. The slides were then 
washed gently in DI water and alcian blue stain was overlaid onto the samples for 30 
minutes. After 30 minutes the slides were rinsed with DI water, and then washed with 3% 
(V/V) glacial acetic acid solution in MQ water to remove excess dye. The cells were then 
gently rinsed again with DI water and visualized. 
 Computational fluid dynamic modeling 
A simplified model was created in ANSYS 8.1 using a multiphase Volume of Fluid 
model in ANSYS FLUENT 18.2 (ANSYS Inc., Canonsburg, PA). The model consists of 
an inlet, the lattice made of crossing 0.4mm square flow channels, a center void where 
the lattice would be anchored to its support in the system, and an outlet. The object was 
meshed with 28,530 quadrilateral elements. Viscosity was modeled using Naiver-stokes 




equations and simulated using Standard K epsilon. Both energy and species transport 
were included. The SIMPLE pressure-velocity coupling scheme was used to run a 
transient model. Momentum convergence was set to 10-8. The inlet velocity was 
calculated by taking volumetric flow and dividing it by the diameter of the simulated inlet 
to give velocity. The model was validated comparing velocity in the model to dye 
experiments. Shear stress was calculated by equation 3 using reported strain rate. 
𝜏 = η𝛾 
 
Equation 4-3: Shear Stress. Where τ is the shear stress in dynes cm-2, γ is the strain rate (s-1), and 
η is the viscosity of the liquid in dynes cm-2.  
This value was used in conjunction with the lowest flow rate needed to keep the lattice 
wetted. 
 Statistics 
Graphs and statistics were done using Minitab 17 (Minitab Inc., PA). Error bars on 
graphs show 2 standard errors. Student's two‐tailed t‐test was used to determine 
significance for two data sets. Significance of multiple data sets was performed via one-
way ANOVA and Tukey test.  
4.4 RESULTS 
 Scaled System 
The aim of this work was to show high purity, high yield stem cell culture on a 3D 
biocompatible lattice. To do this a scaled model of the system of the Express bioreactor 




was engineered, conserving the main geometry of the reactor chamber and method of 
media handling. PLA was used in leu of cellulosic, as cells tended to grow in clusters on 
cellulosic fibers (data not shown). To accommodate the PLA in an unobtrusive way, two 
stands were also made using 3D printing. To decrease shear from the falling water 
droplet, a 316 stainless steel tip was added to allow seamless flow from the recirculation 
loop to the lattice growth matrix. The full reactor assembly and photo of the system can 
be seen in Figure 4-1. As an easy means of visualizing cells, sampling shelves were built 
into the lattice. This allowed for simple sample harvest and preparation for fluorescent 
microscopy. This sample shelf was constructed in the same geometry as the lattice itself. 
From 3D modeling in Solidworks it was calculated that the 30mm diameter lattice used 
has a theoretical surface area of 225cm2. As a comparison, each 30mm diameter 
repeating layer provides 23.5cm2, which equates to a 32-fold increase in surface area 
when comparing the 3D lattice to the equivalent 2D culture area. 
 CFD Modeling 
To demonstrate the principle of the reactor and extrapolate hydrodynamic forces in the 
lattice, ANSYS FLUENT was used with a simplified model of the growth lattice. SEM 
images (Figure 4-2) of the scaffold were taken to understand the printed geometries and 
properly model the system in FLUENT (Figure 4-3). A dye tracer benchtop experiment 
was used to validate the model. As mentioned, media is cycled to the top of the circular 
lattice and pulled by gravity through the pores. Because mixing is accomplished through 
passive means rather than an impeller, the system is inherently very low shear. This was 
proven by testing a range of flow rates to estimate shear vs flow rate (Figure 4-4). All 
prospective flow rates fell well below 0.4 dynes cm-2. As 0.25mL min-1 resulted in the 




lowest shear while keeping the matrix well wetted, it was the tested flow rate for hMSC 
culture. At this flow rate CFD modeling reported a maximum of 0.0054 dynes cm-2 
(Figure 4-3) and an average of 0.00031 dynes cm-2 (Figure 4-4). The areas of highest 
shear were at the top and bottom center of the matrix insert, where the media was 
entering and exiting the lattice respectively.  
 Spinner flask control 
As a comparison hMSCs growth was also investigated on Cytodex-1 microcarriers in 
small scale spinner flasks. Static cultures (n=6) showed an average doubling time and 
specific growth rate of 119.07hrs ±11.23 and 0.0062 hr-1 ±0.0013 respectively (Figure 
4-5 A). Cells cultured in spinner flasks showed an average doubling time of 113.6hrs 
±23.75 and a specific growth rate of 0.0062hr-1 ±0.0013 (n=3) (Figure 4-5 B). Both are 
significantly longer (p=0.002) compared to lattice reactor (n=5) results, which are 
discussed later. 
 Cell viability on PLA Lattice 
Cell viability was compared between culture substrates and static vs dynamic cultures as 
previous studies with fibrous matrices exhibited increased cytotoxicity. On day 7 of 
cultures, cells were enzymatically lifted and viability was tested via trypan blue staining. 
PLA lattices were removed from culture wells to isolate only cells adherent to the PLA 
lattice. Dynamic PLA cultures from the bioreactor had an average viability of 96.54% 
±2.82. Cells grown in dynamic bioreactor culture on PLA showed no statistically 
significant difference (p=0.98) from static PLA culture plates, with an average viability 
of 96.76% ±3.84. Dynamic PLA showed no difference (p=0.45) from Static PS, which 
had an average viability of 95.13% ±1.07. This is also in agreement with the fact that 




static PLA and PS showed no statistical difference in viability (p=0.38). Therefore, PLA 
showed no detrimental effects on cell viability in both static and dynamic cultures 
compared to conventual culture on treated polystyrene flasks. 
 Dynamic seeding  
Because of the larger channel sized and homogeneity of the lattice, a new seeding 
protocol was developed to increase seeding efficiency. The method that yielded the best 
results was through static settling of the cells. The volume of media the lattice could hold 
was found to be 2mL. Thus, 500,000 cells were resuspended in 2mL of hMSC media. 
This cell rich media was then slowly injected through a Luer lock until liquid had cleared 
the lines. The reactor was then placed into the incubator for 45 minutes to allow cells to 
settle onto lattice and adhere. Hypoxic gas was then overlaid into the system though the 
filter ports and the peristaltic pump was then started. Cells formed confluent monolayers 
towards the top center of the lattice sampling shelf (Figure 4-6). 
 Reactor Culture 
Normoxic reactor culture resulted very similar doubling time as PS control cultures 
(Figure 4-7 A). Because hMSCs normally grow in more comparatively more hypoxic 
conditions in vivo, oxygen tension was investigated as a means of increasing cell 
proliferation. It was found that 1.5% O2 resulted in a four-fold increase in cell yield; 
double that of conventional flask culture methods tested (p<0.001) (Figure 4-7 B). 
Normalized yield to surface area was 13,725 cells cm-2 at 1.5% O2 (Figure 4-7 C).This in-
situ conditioning resulted in the significant increase in specific growth rate (O.0085hr-1 
±0.0005) (Figure 4-7 D). When lifted and analyzed via flow cytometry it was found that 
cells cultured in the bioreactor retained their biomarker phenotype regardless of gas 




composition used for hypoxic treatment (CD105+ CD73+ CD14- CD19-); ANOVA 
showed no significant difference in CD105 (p=0.309), CD73 (p=0.347), CD19 (p=0.676), 
and CD14 (p=0.523) biomarker expression (Figure 4-8). Thus, oxygen tension had a 
drastic effect on cell proliferation, and no effect on biomarker profile. Cultures primed at 
0% and 1% (n=3 for both conditions) produced statistically similar cell yields, and 
cultures primed at 5% and 21% oxygen showed no statistically significant difference via 
Tukey test at 95% CI. Compared to control cultures on static tissue treated PS, the 
dynamic bioreactor culture on PLA produced a higher purity MSCs according to ISCT 
standards, Lifted cells were over 98% dual CD105 and CD73 positive cells in reactor 
culture compared to 94% in static normoxic polystyrene culture (p=0.005) (Figure 4-9 
A). There was no significant difference in the negative markers CD14 and CD19 under 
normoxic (n=9) or 1.5% hypoxic conditioning (n=6) (Figure 4-9 A), and single 
populations of cells were harvested from bioreactors (Figure 4-9 B). Again, cells formed 
monolayers on the PLA filaments much like control cultures on PS dishes (Figure 4-6). 
 Differentiation potential 
As previously discussed, ISCT standards for stem cell purity and identification include 
differentiation ability. To test stemness, osteocyte, adipocyte, and chondrocyte inductions 
were performed stem cells harvested from seven-day bioreactor culture. For inductions 
cells were cultured between 15 to 20 days in their respective, defined ATCC 
differentiation media, after which cells were washed, fixed and stained. After seven days 
in bioreactor culture and hypoxic conditioning the cells retained their ability to 
differentiate into Adipocytes, Chondrocytes, and Osteocytes (Figure 4-10). Control 
cultures were also done in parallel with the inductions and stained with the same dyes. 




Control cultures showed no staining of uninduced cells cultured for 21 days in hMSC 
media. 
4.5 DISCUSSION 
By culturing hMSCs in this scaled down bioreactor, we were able to increase cell yield 
four-fold over conventional flask culture methods. It was found that cells cultured in this 
manner maintained high expression (>97% combined CD105+ and CD73+) of positive 
stem cell markers. PLA did not impact cell viability compared to cultures on polystyrene 
in both static and dynamic culture conditions. CFD modeling shows very low velocities, 
and subsequently low shear inside the lattice matrix. The computational modeling of this 
lattice reactor reports maximum values of 0.0054 dynes cm-2 (Figure 4-3). CFD of stirred 
tank reactors utilizing microcarriers report values of approximately 1 to 5 dynes cm-2, and 
packed bed Fibracell systems report an average shear of dynes cm-2 (Table 4-2). Tubular 
systems with similar laminar flow patterns report average values of 0.98 dynes cm-2.29 
These values all fall within 0.02 to 9 dynes cm-2, a range shown to upregulate osteogenic 
genes and differentiation in hMSCs.15,30,31 The system tested at the parameters 
determined was two orders of magnitude lower than this reference range. 
Surface profile of hMSCs did not change with oxygen percentage, as ranges tested were 
within physiological normoxia and treatment times were comparatively short to other 
hypoxic culturing.32 These findings follow previous findings of oxygen tension 
promoting stem cell proliferation and stemness.33–36 As mentioned previously, cells were 
most concentrated on the top of the fibers. In reality, the cells seem to utilize only the top 




portion of the fibers, which would be a product of their static seeding. This would make 
cell-seeding density closer to 5,000 cells cm-2. 
This combination of hypoxic conditioning and gentle fluid movement may be mimicking 
their niche more closely than static cultures. PLA printed by filament deposition has a 
modulus of elasticity of 3.2, which falls in the range of elasticity of trabecular bone.37,38 
BM-hMSCs are normally harvested from the trabeculae of the iliac crest or head of the 
femur. When these three factors are combined, it creates the normal niche for these stem 
cells, which would explain why the cells perform much better in the dynamic culture 
condition of the reactor compared to static flask culture. 
As a benchmark, hMSCs were cultured on Cytodex 1 microcarriers. The doubling time 
for this cell line grown in spinner flasks was significantly longer compared to culture in 
the lattice reactor. Cells were not characterized via flow cytometry, as even after an hour 
in TrypLE they did not lift from the Cytodex 1 beads. This problem of inadequate cell 
lifting has been noted before.26 Whereas cells cultured in this system had no issue 
dissociating from matrix using CDB and TrypLE.  
Another benefit of this system is the comparative ease of downstream purification 
compared to microcarriers. Microcarrier base culture of stem cells requires extra steps to 
purifying the cells from the beads. Some beads require cell detachment using trypsin, 
resulting in an extra step of straining the microcarriers from the lifted cells. Some 
microcarriers are themselves digested by enzymes, eliminating the need of straining or 
filtering. However, depending on the enzyme cell-cell junction may remain, resulting in 
cell clusters in final product. Furthermore, the byproducts of digestion of these 
microcarriers is still a concern for final formulation and patient administration.39 Per UPS 




<788> removal of microcarriers as particulate matter is recommendation for injected 
products.7 Thus systems using microcarriers for hMSC therapies would require either 
inertial steps or straining and filtration steps to remove microcarriers from cells after 
dissociation, adding complication and potentially decreasing overall yield through 
shear.40,41 Centrifugation of the cells can cause cell clumping and exposes the cells to 
high shear, resulting in product loss.12 Also, filtration and straining have been shown to 
decrease viability of harvested cells.41 In our system this purification step is more robust, 
as cells can be washed in place and lifted with a reduced process related impurities after 
lifting. By using recombinant TrypLE we have shown optimal cell lifting within 15 
minutes. Another avenue of cell lifting in this system is via thermoresponsive polymers. 
P(NIPAM) could be coated into the stationary PLA lattice, and cell lifting would be 
completed by only dropping the temperature.42 This would eliminate the need for 
exogenous enzymes and washes, easing downstream processes and subsequently 
increasing yield. Unlike particulate from microcarriers, the degradation product of the 
PLA lattice dissolves into solution as lactic acid.43 This byproduct can easily be removed 
through buffer exchange, but it is also biocompatible and broken down in the body 
naturally.  
Because of its biocompatibility, cell detachment may not be necessary depending on the 
application. As PLA is biocompatible and similar in rigidity to cancellous bone, hMSCs 
can be expanded and differentiated in-situ. Polymer rigidity can be either avoided or 
exploited for tailored stem cell differentiation. Harder polymers like PLA, polystyrene, or 
polycarbonate (PC) can be printed using high temperature 3D printers, and can be easily 
treated for cell adhesion. Softer, more elastic materials like polyurethane have been used 




for stem cell culture and are also readily available materials for 3D printing.44 Culture on 
more elastic scaffolds, such as alginate encapsulation, can direct hMSCs to differentiate 
into chondrocytes and has been used in established differentiation protocols45,46 
Here we have shown a system for high purity stem cell culture. The system resulted in 
above normal yields for tested systems, while maintaining high expression of stem cell 
biomarkers. The cells lifted from the system were easily dissociated with minimal open-
air steps and required no extra purification. When tested for stemness, the cells readily 
differentiated into osteocytes and were able to differentiate into adipocytes. 
Another possible use of this system is for the production of secreted product, as cells are 
adherent to a stationary scaffold. This system is ideal for secreted proteins and vesicles. 
The cells are bound to the substrate and will release cytokines and exosomes of 
therapeutic interest into circulating media. Research into exosomes has shown their 
usefulness in wound healing and inflammatory diseases.47–49 These vesicles are secreted 
by hMSCs and contain mRNA, cytokines, growth factors, and other signaling molecules 
involved in healing, and are a major interest for regenerative medicine.49 The proposed 
lattice system can be run in perfusion, allowing simple harvest of the secretome while 
cells are held stationary in the reactor. 
4.6 CONCLUSION 
Here we show the successful use of a scale down model of a novel suspended matrix 
bioreactor for the culture of hMSCs. Cells adhered well to PLA lattice and grew as 
monolayers similar to conventional culture techniques. A combinatory effect of low 
oxygen tension and slow recirculation rate of 0.25mL min-1 through the lattice based 




culture resulted in higher than average cell yields compared to conventional expansion 
systems, including static T-flasks and spinner flask with microcarriers. 1.5% O2 gas had 
the best cell growth, resulting in a four-fold increase in overall cell yield. The cells lifted 
from the reactor showed excellent stem cell biomarker expression through flow 
cytometry, showing significant increase over conventional flask culture. hMSCs also 
retained their ability to differentiate into bone, cartilage, and fat cells. Further work into 
scaling this system up needs further investigation. Nonetheless we have shown the 
validity of suspended matrix reactor systems for high purity hMSC production. 
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Table 4-1: Reactor Advantages and Disadvantages for hMSC Culture. Adapted from Liu et al.23 and Kumar 
and Starly.43 
Type Advantages Disadvantages 
Microcarrier 
Support high-density cell culture; regulate 
cell growth and differentiation; serve as 
cell delivery systems. Easy to scale up. 
Easy sampling and cell visualization 
Difficult to harvest cells. Purification from 
microcarriers. Still some possible shear 
issues due to energy required for 
suspension. Limited growth area on 
microcarriers. 
Plate Very similar to flask culture; easy to 
translate. Low shear stress because no 
impellor needed 
Difficult to visualize cells. environment is 
inhomogeneous due to the nutrient and 
oxygen gradient 
Packed bed Provide 3D microenvironment; allow cell 
spatial organization; regulate 
proliferation, differentiation and tissue 
formation. Large SA:V 
Difficult to harvest cells. Difficult to 
visualize cells. Concentration gradients. 








Table 4-2: Comparison of Culture Systems. Volume, available surfaces areas, cell types used, total stem cell yield normalized to volume and surface area, total 
overall yield, doubling time and reported shear rates of various systems. 
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Figure 4-1: Schematic and picture of reactor. A) Exploded diagram of components and how they are 
pieced together. B) Image of assembled reactor. C) Cartoon front-on schematic of how lattice is suspended 
out of media and fluid is recirculated through system. 
  






Figure 4-2: Scanning Electron Microscopy images of 3D Printed PLA. A) Outside side orientation. B) Cut 
interior orientation. C) Top down view of PLA lattice. E) High zoom of Outside side F) Cut interior, and G) 
top-down views. Red red squares denote zoom seen in second row. 
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Figure 4-3: CFD modeling of lattice matrix. A) Velocity contour and B) shear stress. Maximum velocity of 
0.0039m s-1 and maximum shear stress of 0.0056 dyne s cm-2 measured inside the lattice, excluding the inlet 
and outlet. Shear was calculated by multiplying strain rate by the viscosity of the fluid. 
 





Figure 4-4: Inlet Flow Rate vs Average Wall Shear. The lattice matrix was modeled in ANSYS and tested at 
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Figure 4-5: Culture method on A) doubling time and B) specific growth rate of hMSCs. Static cultures 
grown in t75 flasks according to ATCC guidelines. Spinner cultures used Cytodex-1 microcarriers in 
spinner flask. Dynamic culture used PLA lattice as per method 
  






Figure 4-6: hMSCs imaged on PLA Scaffold from bioreactor. Cells underwent a three-day prime at 1.5% 
oxygen and were then cultured out for seven days. Stained with phalloidin (red) and DRAQ5 (blue). A) and 
B) show hMSC on single fiber. C) Low magnification showing hMSC coverage among parallel fibers. D) 
Projected Z-stack of fibers showing cell coverage. Center image shows top view (XY projection). Top and 
side bars show sideways projection (ZX and ZY) 
 





Figure 4-7: hMSC bioreactor culture of varying oxygen tension compared to static culture of same oxygen 
amounts harvested on day 7. A) Doubling time, B) Fold increase, C) Cells per cm2 D) Specific growth rate, 












Figure 4-8: Flow Cytometry of hMSC from Reactors harvested Day seven from varying oxygen tension. 
CD105, CD73, CD19 and CD14 stained cells were analyzed using flow cytometry. No significant 






















































































Individual standard deviations are used to calculate the intervals.
Surface Marker Characterization of Lattice Bioreactor Culture






Figure 4-9: hMSC biomarker characterization using flow cytometry. Cells were cultured in both static and 
in bioreactor and compared using CD105, C73, CD19, and CD14 staining. B) Overlaid flow cytometry 
image of 1.5% O2 primed hMSC cultures from D7 bioreactors. 
  
  







Figure 4-10: Stem Cell induction. Cells harvested day seven from bioreactor and cultured out in in 
respective differentiation media following specialized protocols. After allotted time cells were fixed, 
stained, and imaged using light microscopy. Scale bars are 100 microns. 




5 COMPUTATIONAL FLUID DYNAMICS 
5.1 ABSTRACT 
Computational Fluid Dynamics (CFD) is a method of modeling fluid flow and energy 
transfer in silico. In bioprocessing this technique is used both to optimize and 
characterize cell culture systems. In this study we use CFD to better understand 
hydrodynamic forces and flow regimes within the lattice of the bioreactor. For this we 
modeled flow in a 2D model of the scaffold insert of reactor. This was accomplished by 
alternating 400µm by 400µm squares representing the cross sections of the polylactic 
acid fibers. Alternating the fibers made the model match flow patterns seen in benchtop 
dye experiments, bring 3D flow patterns into the 2D simulation. We found that laminar 
flow through the channels of the PLA lattice is predicted to only produce a maximum of 
8.0x10-4 dynes cm-2. We also calculated the KLa to be 2.14 hr-1, very similar to other un-
sparged culture vessels for stem cell bioproduction. This prediction confirms laboratory 
testing of the system were sensitive cell types cultured well in the scaffold. 
5.2 INTRODUCTION 
In this work we use CFD and fluidic validation techniques to characterize a novel low 
shear bioreactor for use with sensitive cell types. We accomplish this by using a 
simplified model in ANSYS 18.2 Fluent and show that when run within certain 
boundaries will provide an acceptable environment for the culture of human 
Mesenchymal Stem Cells (hMSCs). This type of adult stem cell is found in many tissues, 




but is mainly sourced from adipose, bone marrow, or umbilical cord blood.1 hMSCs have 
been shown to react to shear stresses, often differentiating into osteocytes and decreasing 
overall stem cell yield when bioproducing this cell type for regenerative medicine.2 Thus, 
being able to model a system aimed at producing pure hMSCs as a product allows 
researchers to characterize the shear stresses the cells may be exposed too, moving design 
from long and expensive benchtop studies to relatively faster and cheaper in silico 
modeling. 
CFD is a field of applied mathematics aimed at computing fluid flow and forces. CFD 
works by numerically calculating fluid flow and resulting forces. It does this by solving 
Navier-Stokes equations for mass, momentum, and energy conservation. To accurately 
and timely solve for these values the area of fluid flow is broken down into smaller 
geometries called elemental volumes. The discretization of a geometry into elemental 
volumes is a process known as meshing. The solver can then calculate desired equations 
for these cells based on methods including Finite Difference Modeling (FDM), Finite 
Volume Modeling (FVM), and Finite Element Modeling (FEM), with FEM being the 
most common.3 
CFD is a valuable tool for the characterization of bioreactor design and operation.4,5 does 
not eliminate benchtop experiments, but it can decrease the amount of time and cost of 
designing systems. It can also be used to characterize existing stir tank bioreactor 
systems, with a common application being to test impeller speeds vs mixing and shear.6 
CFD modeling for adherent stem cell bioreactors can be used to determine shear stress 
where media flow can affect cells. In the system tested here it allows the user to 
understand fluid flow patterns through a porous matrix. It can also be used as a means of 




ensuring that concept reactors will operate as intended, elucidating problem areas, such as 
in concept reactors before mass production. It has also been very helpful in designing 
scale models for cell culture, much like the system tested within.7,8 the ability to rapidly 
test shear, mixing, pressure, and other parameters important in culture make CFD 
modeling very useful when developing systems for sensitive cells, such as stem cells. 
With regards to bioreactor culture specifically to these cells, CFD is invaluable for 
quantifying how the geometry of the scaffold and supplementation of media impacts fluid 
patterns and flow, velocity distribution and shear, as well as liquid mixing and related gas 
transfer coefficients. As stated previously, CFD can also reduce the burden of benchtop 
experiments, cutting cost of testing and increasing speed of development. All these 
factors combined make CFD an ideal tool when developing and testing systems designed 
to meet the high demand of biologically produced drugs and whole cell therapies.  
The objective of this study was to  utilize CFD  to model fluid flow in the scaffold in a 
similar fashion to other fixed bed systems.9 Flow regimes in such reactors are usually 
lamiar due to the slow speed of media flow. Laminar flow is defined by Reynolds 
Number (Re), where a system with a Re less than 2300 is considered laminar. For a pipe, 
or through channels like in this system, a Re less than 1000 is laminar flow. This means 
that there is no turbulence in the system and flow move steadily with little mixing. While 
turbulence drives mixing in many systems, it is important with stem cells to keep strong 
hydrodynamic forces to a minimum. To accomplish this, systems for stem cell culture 
often operate at much slower flow rates, but this can lead to media gradients and low 
oxygen diffusion. To compensate for this special geometries can be used to drive mixing 




in a way that does not increase the amount of shear the cells are exposed to. Reynolds 





Equation 5-1: Reynolds Number. Where ρ is the density of the fluid, V is the velocity of the fluid moving 
through the pipe, d is the diameter of the pipe, and η is the viscosity of the fluid at a given temperature.  
The oxygen transfer rate into the system is also a valuable tool to determine bioreactor 
performance, usually reported as the transfer coefficient KLa. This value can be 
calculated in CFD by modeling turbulence, or is some small cases through laminar 
modeling.10,11 KLa is incredibly important for bioreactor culture. In most systems oxygen 
is the limiting factor for cell growth.12 A system with higher KLa can provide more 
oxygen to cells. It is because of this that constant KLa has become a standard value to use 
when scaling systems, from clonal selection to large scale culture.13  
Mass transfer regimes can also be calculated using CFD. Péclet number is a 
dimensionless number and is the ratio of advection rate to the diffusion rate. Using Péclet 
number one can deduce whether the movement of gasses and nutrients in the media are 
diffusing through mechanical mixing via fluid flow, or through molecular diffusion. 




= 𝑅𝑒𝐿 𝑆𝑐 
Equation 5-2: Péclet Number. Where L is the characteristic length, u is the local velocity and D is the mass 
diffusion coefficient.  




Péclet Number is also the product of the Reynold number and the Schmitt number. In 
water, the diffusion coefficient of air is 2.0x10-5cm s-1.14,15 Using this information the 





Equation 5-3: Schmidt Number. Where µ is the dynamic viscosity of the fluid, ρ is the density of the fluid, 
and D is the mass diffusivity. 
In our system the shear stress is a byproduct of the velocity gradient of the fluid flowing 
parallel to a surface, and is a property of the viscosity of the fluid. Velocity will be slower 
closer to the wall of a pipe, and faster towards the center. This leads to a velocity 
gradient, and near the walls where shear is the highest known as the boundary layer. 
Shear stress can be calculated from the strain rate following the equation: 
𝜏 = 𝜂𝛾 
Equation 5-4: Shear Stress. Where τ is the shear stress, γ is the strain rate, and η is the viscosity of the 
liquid.  
As strain rate in the system is calculated spatially, this accounts for the distance from the 
walls of the lattice. Thus, a wholistic map of shear stress can be obtained using this 
equation. 
5.3 METHODS 
 Computer rendering and machining 
Solidworks Computer Aided Design (CAD) software was used to generate three 
dimensional designs of the bioreactor scaffold for in silico simulations and experimental 




studies. This allowed model with behavior of flow for multiple geometries to optimize 
both scaffold and reactor designs prior to 3D printing and machining. The scaffold, 
comprising of fibers forming a homogenous lattice, was then 3D printed in PLA using 
Printrbot Simple Metal printer.  
The reactor tested here is a scaled system of the Express bioreactor manufactured by 
Sepragen.  To produce a quality model parts were modeled in Solidworks and physical 
fits were tested via 3D printing, allowing easy design changes prior to machining the 
system from stainless steel. After test fitting and addition of a sampling port and various 
adapters the files were organized in Fusion 360 and milled on a CNC adapted Bridgeport 
milling machine in 316 stainless steel. 
 ANSYS Modeling 
A simplified 2D cross-sectional model of the scaffold geometry was rendered using 
Design Modeler within ANSYS 18.1. A 2D model was used and was adequate to capture 
the flow dynamics of the reactor due to the scale and repetition of the scaffold 
geometries.  The scaffold itself is comprised essentially of one unit that is repeated in a 
lattice pattern. Designing the model like this reduced the computation time required while 
providing and accurate characterization of fluid flow through the lattice. The scaffold was 
prioritized, as it would be where the cells reside while culturing, and because it is the 
narrowest point of the system and would theoretically result in the highest shear. 
FLUENT was used to model fluid flow through the system. Turbulence was modeled 
using k-epsilon in a VOF model using SIMPLE. Convergence was set to 10-8. 
A 2D model was used to monitor tracer infiltration into the modeled lattice. The pressure-
velocity coupling solution method used SIMPLE, gradient of lease squares cell based, 




pressure of PRESTO!, Second order upwind for momentum, geo reconstruct for volume 
fraction, first order upwind for turbulent kinetic energy and for turbulent dissipation rate, 
and second order upwind for energy. First order implicit was used for transient 
formulation. A tracer with the same properties as water was modeled into the system. 
After initialization the tracer was patched into the inlet and the simulation run for 
simulated three minutes. This was chosen because of the time it took for dye to flow 
through the entire system in the benchtop model. 
 Benchtop Dye testing 
To validate CFD modeling the velocity and fluid movement was visualized using dye 
flowing through the PLA scaffold. The lattice was first wetted with MilliQ water and set 
up with the same nozzle as in the bioreactor. Fluid was handled via a peristaltic pump. 
The media line above the inlet to the lattice matrix was teed to allow a pulse of water-
based dye into the loop. After the system had run long enough to purge air from the lines 
and reach a steady state flow the pump was temporarily paused and the dye pushed into 
the inlet until the color was seen beading on the tip of the inlet. The pump was then 
reinitialized, and the matrix was filmed until it was saturated with color. Time points of 
the video were then clipped and used as a visual comparison for CFD validation of 
velocity and liquid movement. 
 Kla and Oxygen Transfer 
To determine the coefficient of oxygen transfer of the bioreactor the system was filled 
with 30mL of PBS and heated to 30°C and run at 0.5mL min-1. Pyroscience FireStingO2 
dissolved oxygen (DO) system was used in conjunction with their small-scale flow 
through sensor. Air was bubbled into the water inside the reactor until DO reading 




stabilized, at which point the probe was set to 100% DO. The media was then bubbled 
with nitrogen to strip the system of oxygen until the reading stabilized, at which point the 
probe was zeroed. Gas was pumped into the headspace for 3 minutes to strip nitrogen and 
DO was measured over time. Oxygen percent [C] was correlated to concentrations and a 
plot of ln(C*-C) vs time to obtain the KLa. The maximum Oxygen Transfer Rate was 
then calculated using the equation: 
𝑂𝑇𝑅 = 𝐾𝐿𝑎(𝐶
∗ ∗ 𝐶) 
Equation 5-5: Oxygen Transfer Rate (OTR). Where OTR is in mMol O2L-1 hr-1, KLa is the oxygen transfer 
coefficient in hr-1, C*is maximum oxygen saturation of media at that given temperature and pressure in 
mMol O2L-1, and C is recorded saturation. For OTRmax C is zero, making OTR a function of KLa and 100% 
saturation of the media. 
5.4 RESULTS 
Early 2D modeling in CFD were not matching dye testing. The PLA lattice tested showed 
good dye infiltration across the lattice insert, while initial models showed tracer moving 
straight through. This was because when the geometry was converted to 2D, there were 
direct channels for the fluid to move down, which was highly favored over horizontal 
tracer movement. To fix this and better match the model to the fluid dye movement seen 
in benchtop experiments, alternating fiber “holes” were patterned into the modeled 2D 
lattice. This led to higher fidelity between the model and benchtop testing. The modeled 
fibers were left as square due to the deposition method of printing. While the body of the 
fibers are more rounded, there is compression of the layers at the joints, causing those 
intersections to be more angular. This also helped to make meshing easier, resulting in a 
more uniform mesh (Figure 5-1). Located halfway between the center and the top of the 




reactor are two rows of larger channels running horizontally. This is to mimic the gap left 
in the lattice from the removable insert that resides there (Figure 5-2). 
The simplified model agreed very well with actual tests at calculated equivalent flow rate. 
The dye test in Figure 5-3 shows dye infiltration and dispersion in the model and the 
tested scaffold. After model validation through dye testing Figure 5-3 a range of shear 
values vs the flow rate of the pump was tested. Flow rates tested were between 0.125 and 
1.00mL. Shear stress values in dynes cm-2 were calculated by multiplying the strain rate 
by the viscosity of the fluid according to Equation 5-4. The calculated minimum and 
maximum rates were 1.3x10-3 and 8.0x10-3 dynes cm-2. Average and maximum shear 
values vs flow rates can be seen in Table 5-1. 
The simplified model run at 0.25mL min-1 showed expected velocity profile through 
fibers. Velocity was highest at the inlet and the outlet where fluid was concentrated. The 
velocity slows as the lattice expands in the middle and the fluid disperses through many 
channels. Strain rate mirrors the velocity profile (Figure 5-5). 
By graphing the log difference in oxygen saturation of the media over time we were able 
to calculate the KLa of the system to be 2.14hr
-1 (Figure 5-6). From this OTRmax was 
found to be 16.26mMol L-1 hr-1. 
Flow was characterized as laminar by calculating Reynolds number. Using the average 
fluid velocity of 0.000172m s-1 through a 0.4mm diameter opening the Reynolds number 
was found to be 2.88x10-3 Via Equation 5-1. This indicates very laminar flow through the 
channels of the PLA lattice. Average Péclet number in the channels was calculated and 
found to be 21 via Equation 5-2. When horizontal velocity was used to calculate Péclet 




the result was 0.01, meaning that mass transfer within horizontal channels is mainly 
through diffusion. Thus, mass transport of oxygen through the channels differ via the 
direction. In vertical channels transport is driven though advection. 
By using cell specific oxygen uptake rate, we can calculate under equilibrium what the 
gas dependent maximum cell density achievable would be. Researchers report that bone 
marrow derived hMSCs have a cell specific OUR of 9.8x10-11 mMol cell-1 hr-1.16 
5.5 DISCUSSION 
Initial flow rates were based on values found in literature, where researchers were 
culturing shear sensitive mammalian cells in dynamic flowing system.17 All tested flow 
rates resulted in shear values less than reported shear stresses shown to drive 
differentiation in mesenchymal stem cells (0.02 -22 dynes cm-2)2,18 (Figure 5-4). 
However, because shear is a source of impurities in cell yields the system was still 
operated at the lowest feasible flow rate. This meant that the reactor was circulated at 
0.25mL min-1, as it was the slowest rate that still wetted the surface of the lattice. 
Velocity was high at the inlet because a fully developed fluid flow is entering narrowed 
channels (Figure 5-5). The velocity quickly dissipates through the lattice as the fluid 
becomes more dispersed through the structure. As these individual velocities begin to 
combine in the bottom half of the reactor, we see fluid velocity begin to increase. This is 
similar to other rigid lattice systems tested using similar fluidics modeling techniques.19 
However, since fluid was moving freely though the system and not forcedly pumped 
across the matrix, there is no pressure drop in this system and shear is comparably much 
less in. As expected, strain rate mirrored velocity contours; shear was highest at the inlet 




and outlet of the matrix. However, even the maximum shear stress values within the 
lattice where cells are attached fall well below reported values of 0.4-9 dynes cm-2 that 
have resulted in stem cell differentiation.2 This is important as it has been shown that 
exposure even as low as 0.02 dynes cm-2 can lead to upregulation of osteocyte markers.18 
The calculated KLa is similar to the approximate 2.00hr
-1 reported in stirred systems 
using gas overlay without sparging.20,21 It is also within the range of 1.59-3.00hr-1 
reported in a specialized system using gyroscopic mixing. 22 The lattice system tested 
here also had higher KLa values compared to spinner flasks which, were reported to be 
between 1.00-1.91hr-1.22 This rough similarity in KLa is likely due to the fact that gas 
exchange in all of these systems is happening passively at the interface of the media and 
the gas in the chamber. Since all methods mentioned are run with the intention of 
decreasing shear, and consequently do not used forced oxygenation of the media, it is 
reasonable that the KLa would be similar. It is also well above the reported KLa value 
theoretically needed to sustain hMSC proliferation in a reactor.23 
Using KLa we can calculate the theoretical maximum cell density. In steady state the 
maximum oxygen transfer rate of the tested lattice system was calculated to be 16.264hr-
1. Dividing this by cell specific OUR obtained from literature, we were able to determine 
that gas exchange is not the limiting factor of the system. Furthermore, we can calculate 
the theoretical maximum cell density. Using reported values, the maximum OTR of this 
system could sustain up to 1.66x1011 bone marrow derived hMSCs. Knowing this, scaling 
of the system is very possible, and the limiting factors would be surface area and 
nutrients in media rather than oxygen transfer.  




Using Péclet number we can conclude that mass transfer varies slightly within the lattice 
based on the channel orientation. In horizontal connecting channels mass transfer of air is 
mainly accomplished through passive diffusion, while vertically oriented channels are 
predicted to have more transfer through advection. 
5.6 CONCLUSION 
Here we have successfully modeled the 3D PLA lattice used to culture hMSCs. This 
modeling allows us to better characterize and understand the forces at play in this system. 
For future experiments CFD will be invaluable for scaling the system. In silico modeling 
of larger matrix inserts and smaller fiber diameters will allow rapid testing without using 
consumables.  
The system shows marginally better KLa than comparable systems, including stirred 
systems commonly used with microcarrier culture of stem cells. This increase may be due 
in part to the unique way the cell culture scaffold is suspended outside of the media, 
resulting in only a very thin layer of media between the cells and atmosphere. 
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Figure 5-1: Scaffold Modeling used for CFD. A) Image of 3D printed PLA lattice. B) design of 2D model 
and mesh comprised of nodes and quadrilaterals used to solve for fluid motion and forces. 
  





Figure 5-2: PLA Lattice used in bioreactor culture. A) Solidworks mock-up of lattice. B) 3D printed lattice 
showing removable piece halfway retracted from the lattice body. 
  






Figure 5-3: Dye testing of flow through lattice matrix. Fluid velocity calculated to me 0.00368m s-1 was 
tested using transient modeling on FLUENT in Ansys 18.2 as an inlet patch. This was compared to dye 
tests at the same flow rate (Middle row). Bottom row is the same as top row, only dye is provided 
continuously. 
  














































Figure 5-5: CFD modeling of lattice matrix. A) Velocity contour and B) wall shear stress. Maximum 
velocity of 0.0039m/s and maximum shear stress of 0.0056 dynes cm-2 measured inside the lattice, 
excluding the inlet and outlet. Shear was calculated by multiplying strain rate by the viscosity of the fluid. 
  





Table 5-1: Flow rate vs average and maximum shear stress 
Flow Rate Average Shear Stress Maximum Shear 
Stress 
mL min-1 Dynes cm-2 Dynes cm-2 
0.125 0.00131 0.00252 
0.25 0.00306 0.00589 
0.5 0.00416 0.00799 
0.75 0.00665 0.01274 
1 0.00831 0.01591 
 
  






Figure 5-6: Kla calculation plot showing ln(C*-C) vs flow rate vs time. Resulting slope is the Kla hr-1. 
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In this work we have designed and characterized a novel 3D culture system for the 
proliferation of mesenchymal stem cells (hMSCs). The system consists of a cylindrical 
body made of clear polycarbonate. It is capped by two plates on either side, with a 
passthrough port to allow sampling of the scaffold. The system allowed for media 
circulation through external peristaltic pumping. 
The scaffold area chosen for studies was a 3D printed polylactic acid (PLA) 
thermoplastic lattice printed on a hobbyist printer. The lattice was made as a 
crosshatching grid, increasing surface area substantially. PLA was chosen for its special 
properties, including: ease of printing, similar rigidity to cancellous bone, 
biocompatibility and biodegradability. Cells readily adhered to the polymer and were 
easily removed from it as well, a key consideration when the cell is the product of the 
system. 
The system worked better for hypoxic priming of the cells compared to a conventional 
static hypoxia chamber. And overall this hypoxic preconditioning of the hMSCs resulted 
in increased yields, averaging 4-fold over seeding density without detrimentally 
impacting stemness. After seven days of culture the stem cells retained their cell surface 
biomarker (CD105+ CD73+ CD19- CD14-) and could still give rise to adipocytes, 
chondrocytes, and osteocytes after 21-day induction in specified medias. Of the oxygen 
mixes used, we found a 1.5% O2 in nitrogen worked best when exposure was kept to a 3 
days and the recirculation was kept at 0.25mL min-1. This resulted in the best and most 
reproducible results. 




To understand the reactor better we employed CFD to elucidate flow and hydrodynamic 
forces. This allowed us to simulate fluid movement through the small geometries of the 
lattice. What we saw was that fluid was moving uniformly and slow through the lattice, 
resulting in very low shear. The KLa of the system matched other reported values for 
other passively aerated systems. Overall, a lattice of this design suspended out of the 
media lead to an ideal low shear environment for stem cell culture while retaining high 
cell purity and viability. 




7 FUTURE DIRECTION 
Testing of other coatings should be performed on the PLA. With gelatin we were able to 
form monolayers very easily, but it is till derived from animal sources. What I suggest is 
to revisit the plasma treatment on PLA combined with a xeno-free coating. The plasma 
treatment drastically increases the wettability of the scaffold, which would help combat 
the drying of the lattice and allow better seeding. It would also eliminate animal sources 
from the system if combined with serum free media. To do this I would treat the lattice in 
the plasma cleaner as described before, but instead of PBS washing and plating the cells 
directly onto the scaffold I would use the resulting charge to coat the PLA with another 
polymer. The two that come to mind are poly-lysine and PNIPAAM. Poly-lysine has 
been used to coat tissue culture plastics, which hMSCs will ready adhere to and grow on. 
It is not derived from animals, a huge benefit if any hMSC based product is to go to the 
FDA. PNIPAAM is a thermoresponsive polymer and would allow non-enzymatic lifting 
of cells. This would eliminate the use of enzymes, which are either animal derived, or 
recombinant and not very scalable due to price. 
I also suggest scaling of the matrix. As a next step the lattice matrix diameter should be 
increased and tested. CFD would be very helpful in finding the limit of diameter both for 
fluid infiltration in the horizontal, and for oxygen diffusion. What I see happening is 
having a larger diameter matrix with more sampling shelves, but also some larger 5.0mm 
through channels running in the horizontal axis for gas exchange. To better understand 
the fluid mechanics in such a system a more complete 3D model would have to be made. 




This would better elucidate lateral and horizontal movement of the media inside of the 
lattice. 
Lastly, I would have liked to harvest the secretome of the cells grown in this system. 
Exosomes have shown much promise in wound healing and have great potential in 
treating diseases. The regulator pathway for a product like this would be much clearer 
than with a whole cell therapy. What I suggest is seeding and culturing the cells as 
previously described, but omitting the cell lifting strategies. Instead, a tangential flow 
filter or alternating flow filter should be placed in the line with pores ranging from 50 to 
500nm. A secondary peristaltic pump could control permeate, meaning that the flow rate 
of the reactor itself would not have to be adjusted. This would allow controlled passage 
of cell exosomes, which could be collected very easily. As cells are immobilized on the 
scaffold, there should theoretically be very little cell debris reaching the filter. As the 
only byproduct of PLA degradation is lactic acid, as long as pH is monitored well there 
should be low scaffold-based cytotoxicity resulting in undamaged exosomes. 
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9 SUPPLEMENTAL DATA 
 
Figure 9-1: hMSC on 3D printed 3D filament. Cells cultured in bioreactor at 0.25mL min-1 for 7 days with a 3 day 
1.5%O2 prime. Actin is in red and nuclei are in blue. Note actin filament alignment running diagonal following the 
length of the PLA structure. 





Figure 9-2: hMSC on 3D printed 3D filament. Cells cultured in bioreactor at 0.25mL min-1 for 7 days with a 3 day 
1.5%O2 prime. Actin is in red and nuclei are in blue. Note actin aligns with the bend of the PLA structure. 





Figure 9-3: hMSCs cultured on polystyrene tissue culture dishes for 7 days. Green is actin staining and blue are nuclei. 
Note the random alignment of actin filaments. 
  





Figure 9-4: Total surface area vs diameter of 3D printed lattice insert. Calculated via Solidworks modeling. 
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Figure 9-5: hMSC characterization of normoxic and hypoxic culture. Cells grown statically for 7 days on 
polystyrene tissue culture dishes and characterized via flow cytometry. Hypoxic treatment was for three 
days at 1.5% O2. Red is normoxia and blue is hypoxia. The third column is the overlay of the first two 
columns for easier comparison. 





Figure 9-6: hMSC unstained Controls. Cultured for 7 days on polystyrene tissue culture dishes. 





Figure 9-7:Stained control hMSCs. Cells cultured for 7 days on tissue culture polystyrene dishes and stained with 
hMSC markers according to protocol. 





Figure 9-8: Flow Cytometer of 21% O2 bioreactor cultured for 7 days at 0.25mL min-1. 





Figure 9-9: Flow Cytometry of hMSC primed at 0% O2 for three days and cultured for a total of seven days 
in bioreactor at 0.25mL min-1. 





Figure 9-10: Flow Cytometry of hMSC primed at 1.5% O2 for three days and cultured for a total of seven 
days in bioreactor at 0.25mL min-1. 





Figure 9-11: Flow Cytometry of hMSC primed at 5.0% O2 for three days and cultured for a total of seven 
days in bioreactor at 0.25mL min-1. 
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